Dex Liquidating (CRDC) 10-K 12 Oct 16 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Oct. 06, 2016	Dec. 31, 2015
Document Information [Line Items]
Entity Registrant Name	DEXTERA SURGICAL INC
Entity Central Index Key	1,178,104
Trading Symbol	dxtr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		8,927,830
Entity Public Float			$ 13.9
Document Type	10-K
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2016	Jun. 30, 2015
Current assets
Cash and cash equivalents		$ 3,626	$ 8,264
Short-term investments		9,090	12,972
Accounts receivable		313	424
Inventories		1,063	1,391
Prepaid expenses and other current assets		318	310
Total current assets		14,410	23,361
Property and equipment, net		1,178	1,859
Long-term investments			3,970
Restricted cash		104	104
Total assets		15,692	29,294
Current liabilities
Accounts payable		766	699
Accrued compensation		739	434
Other accrued liabilities		517	522
Current portion of deferred revenue		569	403
Total current liabilities		2,591	2,058
Deferred revenue, net of current portion		2,499	2,125
Note payable		3,124	2,828
Other non-current liabilities		196	194
Total liabilities		8,410	7,205
Stockholders’ equity (1)
Preferred stock, $0.001 par value: 5,000,000 shares authorized; 191,474 shares issued and outstanding at June 30, 2016 and 2015	[1]	17,214	17,214
Common stock, $0.001 par value: 125,000,000 shares authorized; 8,934,452 and 8,902,144 shares issued and 8,927,830 and 8,895,521 shares outstanding at June 30, 2016 and 2015, respectively	[1]	9	9
Additional paid-in capital		196,355	195,179
Treasury stock at cost (6,622 shares at June 30, 2016 and 2015)		(596)	(596)
Accumulated other comprehensive loss		(4)	(8)
Accumulated deficit		(205,696)	(189,709)
Total stockholders’ equity	[2]	7,282	22,089
Total liabilities and stockholders’ equity		$ 15,692	$ 29,294
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.
[2]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2016	Jun. 30, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	191,474	191,474
Preferred stock, shares outstanding (in shares)	191,474	191,474
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	8,934,452	8,902,144
Common stock, shares outstanding (in shares)	8,927,830	8,895,521
Treasury stock, shares (in shares)	6,622	6,622

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net revenue
Product sales, net		$ 2,529,000	$ 2,922,000	$ 3,505,000
License and development revenue		1,460,000		41,000
Royalty revenue		66,000	68,000	69,000
Total net revenue		4,055,000	2,990,000	3,615,000
Operating costs and expenses
Cost of product sales		3,897,000	4,235,000	4,770,000
Research and development		6,327,000	7,341,000	6,883,000
Selling, general and administrative		9,388,000	10,197,000	8,463,000
Total operating costs and expenses		19,612,000	21,773,000	20,116,000
Loss from operations		(15,557,000)	(18,783,000)	(16,501,000)
Interest income		62,000	56,000	12,000
Interest expense		(497,000)	(450,000)	(504,000)
Other income (expense), net		5,000	(5,000)	27,000
Net loss before income tax		(15,987,000)	(19,182,000)	(16,966,000)
Income tax benefit
Net loss	[1]	(15,987,000)	(19,182,000)	(16,966,000)
Deemed dividend related to beneficial conversion feature of convertible preferred stock				(1,915,000)
Net loss allocable to common stockholders		$ (15,987,000)	$ (19,182,000)	$ (18,881,000)
Basic and diluted net loss per share allocable to common stockholders(1) (in dollars per share)	[2]	$ (1.79)	$ (2.16)	$ (3.24)
Shares used in computing basic and diluted net loss per share allocable to common stockholders(1) (in shares)	[2]	8,910	8,895	5,833
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.
[2]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parentheticals)	Feb. 17, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Reverse Stock Split [Member]
Reverse stock split	10	10	10	10

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net loss	[1]	$ (15,987,000)	$ (19,182,000)	$ (16,966,000)
Other comprehensive loss:
Change in unrealized loss on investment	[1]	4,000	2,000	(5,000)
Comprehensive loss		$ (15,983,000)	$ (19,180,000)	$ (16,971,000)
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Convertible Preferred Stock [Member]Preferred Stock [Member]	Convertible Preferred Stock [Member]Common Stock [Member]	Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]	Convertible Preferred Stock [Member]Treasury Stock [Member]	Convertible Preferred Stock [Member]AOCI Attributable to Parent [Member]	Convertible Preferred Stock [Member]Retained Earnings [Member]	Convertible Preferred Stock [Member]	[1]	MLV [Member]Preferred Stock [Member]	MLV [Member]Common Stock [Member]	MLV [Member]Additional Paid-in Capital [Member]	MLV [Member]Treasury Stock [Member]	MLV [Member]AOCI Attributable to Parent [Member]	MLV [Member]Retained Earnings [Member]	MLV [Member]	[1]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Jun. 30, 2013																		5,106,861
Balance at Jun. 30, 2013																		$ 5	$ 165,131	$ (596)	$ (5)	$ (153,561)	$ 10,974	[1]
Issuance of common stock upon release of restricted share units (in shares)																		12,267
Issuance of common stock upon release of restricted share units
Sale of common stock, net of issuance costs (in shares)	191,474									43,916								3,737,500
Sale of common stock, net of issuance costs	$ 15,299						$ 15,299				$ 450				$ 450			$ 4	29,409				29,413	[1]
Deemed dividend related to beneficial conversion feature of Series A preferred stock																	1,915		(1,915)
Stock-based compensation expense																			1,020				1,020	[1]
Net loss																						(16,966)	(16,966)	[1]
Change in unrealized loss on investment																					(5)		(5)	[1]
Balance (in shares) at Jun. 30, 2014																	191,474	8,900,544
Balance at Jun. 30, 2014																	$ 17,214	$ 9	194,095	(596)	(10)	(170,527)	40,185	[1]
Issuance of common stock upon release of restricted share units (in shares)																		1,600
Issuance of common stock upon release of restricted share units
Sale of common stock, net of issuance costs																			(65)				(65)	[1]
Stock-based compensation expense																			1,149				1,149	[1]
Net loss																						(19,182)	(19,182)	[1]
Change in unrealized loss on investment																					2		2	[1]
Balance (in shares) at Jun. 30, 2015																	191,474	8,902,144
Balance at Jun. 30, 2015																	$ 17,214	$ 9	195,179	(596)	(8)	(189,709)	22,089	[1]
Issuance of common stock upon release of restricted share units (in shares)																		32,308
Issuance of common stock upon release of restricted share units
Stock-based compensation expense																			1,176				1,176	[1]
Net loss																						(15,987)	(15,987)	[1]
Change in unrealized loss on investment																					4		4	[1]
Balance (in shares) at Jun. 30, 2016																	191,474	8,934,452
Balance at Jun. 30, 2016																	$ 17,214	$ 9	$ 196,355	$ (596)	$ (4)	$ (205,696)	$ 7,282	[1]
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Consolidated Statements of Sto8

Consolidated Statements of Stockholders' Equity (Parentheticals) $ in Thousands	12 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Additional Paid-in Capital [Member] | Convertible Preferred Stock [Member]
Stock issuance costs		$ 1,000
Additional Paid-in Capital [Member] | MLV [Member]
Stock issuance costs		51
Additional Paid-in Capital [Member]
Stock issuance costs	$ 100	$ 2,300
Reverse Stock Split [Member]
Reverse stock split	10	10

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	[1]	$ (15,987,000)	$ (19,182,000)	$ (16,966,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization of property and equipment		894,000	1,255,000	1,387,000
Amortization of premiums on marketable securities		172,000	437,000	126,000
Loss on disposal or retirement of property and equipment		37,000	86,000	60,000
Stock-based compensation expense on grants of stock awards to non-employees			65,000	107,000
Stock-based compensation expense on grants of stock awards to employees		1,176,000	1,084,000	913,000
Allowance for doubtful account				(33,000)
Non cash interest expense		296,000	251,000	304,000
Changes in assets and liabilities
Accounts receivable		111,000	282,000	(282,000)
Prepaid expenses and other current assets		(8,000)	39,000	(96,000)
Inventories		328,000	(305,000)	371,000
Accounts payable and other accrued liabilities		68,000	(101,000)	171,000
Accrued compensation		305,000	(465,000)	299,000
Deferred revenue		540,000		(41,000)
Other non-current liabilities		(4,000)	128,000	(128,000)
Net cash used in operating activities		(12,072,000)	(16,426,000)	(13,808,000)
Investing activities
Purchases of property and equipment		(250,000)	(664,000)	(822,000)
Proceeds from maturities of investments		24,822,000	30,334,000	8,648,000
Purchases of investments		(17,138,000)	(30,468,000)	(20,000,000)
Net cash (used in) provided by investing activities		7,434,000	(798,000)	(12,174,000)
Financing activities
Proceeds from sales of convertible preferred stock, net of issuance costs				15,299,000
Proceeds from sales of common stock, net of issuance costs			(65,000)	29,863,000
Net cash (used in) provided by financing activities			(65,000)	45,162,000
Net increase (decrease) in cash and cash equivalents		(4,638,000)	(17,289,000)	19,180,000
Cash and cash equivalents at beginning of year		8,264,000	25,553,000	6,373,000
Cash and cash equivalents at end of year		3,626,000	8,264,000	25,553,000
Supplemental disclosure of cash flow information
Cash paid for interest		200,000	200,000	200,000
Supplemental disclosure of non-cash investing and financing information
Deemed dividend related to beneficial conversion feature of convertible preferred stock				1,915,000
Incremental debt discount relating to note extension			$ 515,000
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1. Organization and Summary of Significant Accounting Policies Organization Dextera Surgical Inc. ( the “Company”) was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc., and on June 19, 2016, changed its name to Dextera Surgical Inc. The Company is commercializing and developing the MicroCutter 5/80™ stapler based on its proprietary “staple-on-a-strip” technology intended for use by thoracic, pediatric, bariatric, colorectal and general surgeons. The Company rebranded the latest version of its MicroCutter XCHANGE® 30 combo device as Dextera MicroCutter 5/80™ stapler, which is currently commercially available, is a cartridge-based microcutter device with a 5 millimeter shaft diameter, 80 degrees of articulation, and a 30 millimeter staple line approved for use specified indications for use in the United States and in the European Union, or EU, for a broader range of specified indications of use. The Company previously had additional products in development, including the MicroCutter XCHANGE® 45, a cartridge-based microcutter device with an 8 millimeter shaft and a 45 millimeter staple line, and the MicroCutter FLEXCHANGE™ 30, a cartridge-based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling; however, the Company suspended development of these additional potential products to focus solely on development of the first MicroCutter XCHANGE 30, and now the MicroCutter 5/80. In March 2012, the Company completed the design verification for and applied Conformité Européenne, or the CE Mark, to the MicroCutter XCHANGE 30 (where the Company uses the term “MicroCutter XCHANGE 30” herein, the Company refers to earlier versions of the MicroCutter XCHANGE 30, not the latest version that the Company rebranded as the MicroCutter 5/80) and, in December 2012, began a controlled commercial launch of the MicroCutter XCHANGE 30 in Europe. The Company received from the United States Food and Drug Administration, or FDA, 510(k) clearances for the MicroCutter XCHANGE 30 and blue reload in January 2014, and for the white reload in February 2014, for use in multiple open or minimally-invasive surgical procedures for the transection, resection and/or creation of anastomoses in small and large intestine, as well as the transection of the appendix. The blue reload is a cartridge inserted in the MicroCutter XCHANGE 30 to deploy staples for use in medium thickness tissue, and the white reload is a cartridge inserted in the MicroCutter XCHANGE 30 to deploy staples for use in thin tissue. In March 2014, the Company made its first sale of the MicroCutter XCHANGE 30 in the United States, and subsequently temporarily suspended its controlled commercial launch in November 2014, as the Company shifted its focus to improved performance based on surgeons’ feedback. In April 2015, the Company resumed its controlled commercial launch primarily in Europe, of the MicroCutter XCHANGE 30 for thinner tissue usually requiring deployment of white reloads. In November 2015, the Company issued a voluntary withdrawal of the MicroCutter XCHANGE 30 blue cartridges from the market, and continued to sell the MicroCutter XCHANGE 30 device solely for use with the white cartridge. While the Company continues this controlled commercial launch, the Company’s goal was to complete product improvements on the MicroCutter 5/80 which accommodates thicker tissue by enabling deployment of both white and blue reloads. The Company has since ceased the production of the MicroCutter XCHANGE 30 and although it will continue to sell the MicroCutter XCHANGE 30 until the Company has depleted the remaining finished goods inventory, it is focusing on producing and selling the MicroCutter 5/80. To further expand the use of the MicroCutter 5/80, the Company submitted 510(k) Premarket Notifications to the FDA to expand the indications for use to include vascular structures, and in January 2016, received FDA 510(k) clearance to use the MicroCutter 5/80 with a white reload and in July 2016, received FDA 510(k) clearance to use the MicroCutter 5/80 with a blue reload, both for the transection and resection in open or minimally invasive urologic, thoracic, and pediatric surgical procedures. These clearances complement the existing indications for use of the MicroCutter 5/80 in surgical procedures in the small and large intestine and in the appendix. Following the 510(k) clearances, the Company is currently conducting its evaluation of the MicroCutter 5/80, that deploys both blue and white cartridges, with selected centers of key opinion leaders throughout the U.S. and Europe through initial market preference testing to validate the clinical benefits prior to broadening its commercial launch. The Company also initiated the MATCH registry, a post-market surveillance registry, the MicroCutter-Assisted Thoracic Surgery Hemostasis (“MATCH”) registry to evaluate the hemostasis (stopping of blood flow) and ease-of-use for the MicroCutter 5/80. This is a prospective, open-label, multi-center registry and the Company plans to enroll up to 120 patients requiring surgical stapling during a lobectomy (surgical removal of a lobe of an organ) or segmentectomy (surgical removal of a segment of a lung lobe) at leading centers in the U.S. and Europe. The Company is also attempting to expand use of the MicroCutter 5/80 in the international market with selected regulatory filings. The Company submitted the application to Health Canada for regulatory approval of the MicroCutter XCHANGE 30 and the white cartridge reload and, in March 2016, received a medical device license to market in Canada. Although the Company is licensed to market the MicroCutter XCHANGE 30 with white reloads in Canada, the Company intends to wait until the Company files an amendment for the MicroCutter 5/80 with Health Canada for regulatory approval before it can market the MicroCutter 5/80 in Canada. In addition, in August 2013, the Company’s exclusive distributor in Japan, Century Medical, Inc., or Century, filed for regulatory approval of the MicroCutter XCHANGE 30 white and blue cartridge reloads with the Pharmaceuticals and Medical Devices Agency, or PMDA, in Japan and in April 2014, filed for approval for the MicroCutter XCHANGE 30 with TUV Rheinland Japan Ltd, a registered third-party agency in Japan, and received approvals in late 2014 for both reloads and stapler, to market in Japan. Also, in January 2015, Century submitted an application to PMDA relating to a change in the material of the reload insert component within the reloads, changing the distal tip of the reload insert material from a Vectra Liquid Crystal Polymer, or LCP, to IXEF Polyarylamide, or IXEF, and received approval in August 2015 to market in Japan. Though approvals of the MicroCutter XCHANGE 30 and reloads for marketing in Japan have been obtained, Century intends to wait until the Company releases the MicroCutter 5/80 to Century and Century will need to file additional regulatory approvals with the Ministry of Health to market the MicroCutter 5/80 in Japan. Historically, the Company generated product revenues primarily from the sale of automated anastomotic systems; however, the Company started generating revenues from the commercial sales of the microcutter products since its introduction in Europe in December 2012, and in the United States in March 2014, and through June 30, 2016, the Company generated $1.8 million of net product revenues from the commercial sales of the microcutter products. For the years ended June 30, 2016, 2015 and 2014, the Company generated $0.4 million, $0.7 million and $0.5 million, respectively of net product revenues from the commercial sales of the microcutter products. Going Concern The Company has incurred cumulative net losses of $205.7 million through June 30, 2016, and negative cash flows from operating activities and expects to incur losses for the next several years. As of June 30, 2016, the Company had approximately $12.7 million of cash, cash equivalents and short-term investments, and $4.0 million of debt principal outstanding. The Company believes that the existing cash, cash equivalents and short-term investments will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted for at least the next nine months, subject to the ultimate resolution of the following uncertainty. The Company does not agree with Century’s assertions as the Company believes that it had notified Century of the financing that occurred in April 2014 and the extension of the due date of the note agreement effectively waived the prepayment provisions of the loan. The Company is currently in discussions with Century to resolve this matter. The Company does not believe it is probable that Century would prevail in a legal resolution of this matter. Accordingly, the Company has not changed the classification of the note as a noncurrent liability as of June 30, 2016. Penalty interest has not been reflected in the financial statements as its payment is not considered probable. Additionally, the Company has not accelerated amortization of the remaining note discount ($0.9 million at June 30, 2016). If the Company is required to repay the $4.0 million loan from Century along with the related penalty interest prior to September 30, 2018, this will reduce the period during which the existing cash, cash equivalents and short-term investments will be sufficient to meet the Company’s anticipated cash needs to less than six months from June 30, 2016, which would severely impair our ability to continue our business unless we are able to raise other funds to repay this debt. The Company may be able to extend these time periods to the extent that it decreases its planned expenditures, or raises additional capital. The Company would need to further reduce expenses in advance of the date on which it would exhaust its cash, cash equivalents and short-term investments in the event that it is unable to complete a financing, strategic or commercial transaction in the near term to ensure that it has sufficient capital to meet its obligations and continue on a path designed to create and preserve stockholders’ value. In order to satisfy its longer term liquidity requirements, the Company may seek to sell additional equity or debt securities, obtain a credit facility, enter into product development, license or distribution agreements with third parties or divest one or more of its commercialized products or products in development. The sale of additional equity or convertible debt securities could result in significant dilution to its stockholders, particularly in light of the prices at which its common stock has been recently trading. In addition, if the Company raises additional funds through the sale of equity securities, new investors could have rights superior to its existing stockholders. If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with its common stock and could contain covenants that would restrict its operations. Any product development, licensing, distribution or sale agreements that the Company enters into may require it to relinquish valuable rights, including with respect to commercialized products or products in development that the Company would otherwise seek to commercialize or develop it selves. The Company may not be able to obtain sufficient additional financing or enter into a strategic transaction in a timely manner. Its need to raise capital may require it to accept terms that may harm its business or be disadvantageous to its current stockholders. The Company’s consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuations as a going concern is contingent upon its ability to generates revenue and cash flow to meet its obligations on a timely basis and its ability to raise financing. The Company’s plans may be adversely impacted if it fails to realize its assumed levels of revenues and expenses or savings from its cost reduction activities. However, there can be no assurance that the Company will be able to generate cash flows and raise such funds if and when they are required. Failure to obtain future funding when needed or on acceptable terms would adversely affect its ability to fund operations and continues as a going concern. These matters raise substantial doubt about the ability of the Company to continue in existence as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of Dextera Surgical Inc., and its wholly-owned subsidiary in Germany. All significant intercompany balances and transactions have been eliminated in consolidation. Reverse Stock Split On February 16, 2016, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse split of its outstanding common stock (the “Reverse Split”) which had the effect of reducing the number of outstanding shares of common stock from 89,344,777 to 8,934,452, effective February 17, 2016. Any fractional shares of common stock resulting from the Reverse Split were settled in cash equal to the fraction of a share to which the holder was entitled. As a result of the Reverse Split, the Company reclassified its consolidated balance sheets total par value of approximately $80,000 from common stock to additional paid-in capital for the reporting periods. All shares of common stock, stock options, warrants to purchase common stock, the conversion rate of preferred stock and per share information presented in the consolidated financial statements have been adjusted to reflect the Reverse Split on a retroactive basis for all periods presented and all share information is rounded down to the nearest whole share after reflecting the Reverse Split. Foreign Currency Translation The Company’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense). Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could materially differ from these estimates. Cash and Cash Equivalents The Company’s cash and cash equivalents are maintained in checking, money market, commercial paper and corporate debt securities investment accounts. The Company considers all highly liquid investments with maturities remaining on the date of purchase of three months or less to be cash equivalents. Accounts Receivable Accounts receivable consists of trade receivables and other receivables. Accounts receivable are recorded at net realizable value, which approximates fair value. The Company evaluates the collectability of accounts receivable on a case-by-case basis and makes adjustments to the bad debt reserve for expected losses. The Company considers factors such as ability to pay, bankruptcy, credit ratings, payment history and past-due status of the accounts. If circumstances related to customers change, estimates of recoverability would be further adjusted. For the fiscal year ended June 30, 2014, the Company recovered $33,000 of bad debt reserve that was recorded in the fiscal year ended June 30, 2013. Available-for-Sale Securities Available-for-sale securities consist primarily of corporate debt securities, commercial paper, and certificates of deposit, and, by the Company's investment policy, restrict exposure to any single corporate issuer by imposing concentration limits. Although maturities may extend beyond one year, it is management's intent that these securities are available for use in current operations. The Company held investments in marketable securities as of June 30, 2016 and 2015, with maturity dates of less than one year for short-term and greater than one year for long-term. The Company records its marketable securities at fair value and classifies them as available-for-sale. The cost of securities sold is based on the specific-identification method. Interest on securities classified as available-for-sale is included in interest income. Unrealized gains or losses on available-for-sale securities are classified as other comprehensive income or loss and reported as a separate component of stockholders’ equity until realized. When the resulting fair value is significantly below cost basis and/or the significant decline has lasted for an extended period of time, the Company performs an evaluation to determine whether the marketable equity security is other than temporarily impaired. The evaluation that the Company uses to determine whether a marketable equity security is other than temporarily impaired is based on the specific facts and circumstances present at the time of assessment, which include significant quantitative and qualitative assessments and estimates regarding credit ratings, collateralized support, the length of time and significance of a security’s loss position and intent and ability to hold a security to maturity or forecasted recovery. Investments are summarized as follows (in thousands): As of June 30, 201 6 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Commercial paper – Short-term $ 999 $ — $ — $ 999 Corporate debt securities – Short-term 8,095 — (4 ) 8,091 Total $ 9,094 $ — $ (4 ) $ 9,090 As of June 30, 201 5 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Corporate debt securities – Short-term $ 12,978 $ — $ (6 ) $ 12,972 Corporate debt securities – Long-term 3,972 — (2 ) 3,970 Total $ 16,950 $ — $ (8 ) $ 16,942 The following table summarizes the gross unrealized losses and fair values of investments in an unrealized loss position as of June 30, 2016, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands): June 30, 2016 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) Total $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) June 30, 2015 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 ) Total $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 ) The Company reviews investments for other-than-temporary impairment. It was determined that unrealized losses at June 30, 2016 and 2015, are temporary in nature, because the changes in market value for these securities resulted from the fluctuating interest rates, rather than a deterioration of the credit worthiness of the issuers. The Company is unlikely to experience losses if these securities are held to maturity. In the event that the Company disposes of these securities before maturity, it is expected that any losses will be immaterial. The following tables summarizes contractual underlying maturities of the Company’s available-for-sale investments at June 30, 2016 (in thousands): June 30, 2016 Due one year or less Marketable Securities: Cost Fair Value Commercial paper $ 999 $ 999 Corporate debt securities 8,095 8,091 Total $ 9,094 $ 9,090 Restricted Cash Under an operating lease for its facility in Redwood City, California, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $0.1 million at June 30, 2016 and 2015, has been recorded as restricted cash in the accompanying balance sheets, related to the letter of credit (see Note 5). Concentrations of Credit Risk and Certain Other Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, long-term investments and accounts receivable. The Company places its cash, cash equivalents, short-term and long-term investments with high-credit quality financial institutions. The Company is exposed to credit risk in the event of default by the institutions holding the cash, cash equivalents, short-term and long-term investments to the extent of the amounts recorded on the balance sheet. The Company sells its products to hospitals in the U.S. and Europe and to distributors in Europe, Japan and Saudi Arabia that resell the products to hospitals. The Company does not require collateral to support credit sales. The Company has had insignificant credit losses to date. The following table illustrates total net revenue from the geographic location in which the Company’s customers are located and sales revenue by product line. Net revenue by geographic location: Fiscal Year Ended June 30, 2016 2015 2014 United States 37 % 50 % 45 % Japan 34 % 28 % 29 % Germany 21 % 14 % 15 % Rest of world 8 % 8 % 11 % Sales revenue by product line (in thousands): Fiscal Year Ended June 30, 2016 2015 2014 Microcutter $ 351 $ 684 $ 488 Cardiac (automated anastomotic systems) 2,178 2,238 3,017 Total $ 2,529 $ 2,922 $ 3,505 The following table illustrates concentrations of credit risk for the periods presented. Percent of Total Net Revenue for Fiscal Year Ended June 30, Percent of Total Accounts Receivable as of June 30, 2016 2015 2014 2016 2015 Century Medical 21 % 28 % 29 % 33 % 46 % Herz-Und Diabeteszentrum 8 % 10 % 12 % — — Iona Surgical 1 % 1 % — 20 % 9 % As of June 30, 2016, 2015 and 2014, and for the years then ended, no other customer accounted for equal to or greater than 10% of net revenue or account receivable balances. The Company does not believe that accounts receivable from Century Medical, Herz-Und Diabeteszentrum and Iona Surgical represent a significant credit risk based on past collection experiences and the general creditworthiness of these customers. The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities. Inventories Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, to determine whether adjustments for impairment are required. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Further reduced demand may result in the need for additional inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory. Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows. All long-lived assets are in the United States, and through June 30, 2016, there have been no indications of impairment; therefore, the Company has recorded no such losses. Revenue Recognition The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title has transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment. The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred. Research and Development Research and development expenses consist of costs incurred for internally sponsored research and development, direct expenses, research-related overhead expenses, and costs incurred on development contracts. Research and development costs are charged to research and development expenses as incurred. Clinical Trials The Company accrues and expenses costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. The Company determines the estimates through discussion with internal clinical personnel and outside service providers as to progress or stage of completion of trials or services and the agreed upon fee to be paid for such services. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trial. Deferred Rent Rent expense is recognized on a straight-line basis over the non-cancelable term of the Company’s facility operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent. The current portion of deferred rent is recorded as other accrued liabilities, while the non-current portion is recorded in non-current accrued liabilities. Income Taxes The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2016. Segments The Company operates in a single reporting segment. Management uses one measurement of profitability and does not segregate its business for internal reporting purposes. All of the Company’s long-lived assets are maintained in the United States. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period without consideration of potential common shares. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding for the period less the dilutive potential common shares for the period determined using the treasury-stock method. Dilutive potential common share equivalents are excluded from the computation of net loss per share in the loss periods as their effect would be antidilutive. For purposes of this calculation, options, warrants and underlying convertible preferred shares to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. In the years the Preferred Stock was outstanding, the two-class method was used to calculate basic and diluted earnings (loss) per common share since it is a participating security under ASC 260 Earnings per Share The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except per share data): Fiscal Year Ended June 30, 2016 2015 2014 Numerator: Net loss $ (15,987 ) $ (19,182 ) $ (16,966 ) Deemed dividend related to beneficial conversion feature of convertible preferred stock — — (1,915 ) Net loss allocable to common stockholders $ (15,987 ) $ (19,182 ) $ (18,881 ) Denominator: Weighted-average shares outstanding allocable to common stockholders 8,910 8,895 5,833 Denominator for basic and diluted net loss per share allocable to common stockholders 8,910 8,895 5,833 Basic and diluted net loss per share allocable to common stockholders $ (1.79 ) $ (2.16 ) $ (3.24 ) The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation for the fiscal years ended June 30, 2016, 2015 and 2014, because their effect would be antidilutive (in thousands): As of June 30, 2016 2015 2014 Options to purchase common stock 1,516 456 560 Non-vested restricted stock units and awards 27 19 2 Shares reserved for issuance upon conversion of Series A Preferred 1,915 1,915 1,915 Warrants — — 399 3,458 2,390 2,876 Stock-Based Compensation Stock-based

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurements	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 2. Fair Value Measurements FASB Accounting Standards Codification (“ ASC”) 820, “ Fair Value Measurements and Disclosures Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company does not have any liabilities that are measured at fair value on a recurring basis. All assets that are measured at fair value on a recurring basis have been segregated into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. These assets measured at fair value are summarized below (in thousands): As of June 30, 201 6 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 3,029 $ — $ — $ 3,029 Short-term investments: Commercial paper — 999 — 999 Corporate debt securities — 8,091 — 8,091 Total assets at fair value $ 3,029 $ 9,090 $ — $ 12,119 As of June 30, 201 5 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 6,399 $ — $ — $ 6,399 Corporate debt securities — 668 — 668 Short-term investments: Corporate debt securities — 12,972 — 12,972 Long-term investments: Corporate debt securities — 3,970 — 3,970 Total assets at fair value $ 6,399 $ 17,610 $ — $ 24,009 Funds held in money market instruments, are included in Level 1 as their fair values are based on market prices/quotes for identical assets in active markets. Corporate debt securities and commercial papers are valued primarily using market prices comparable securities, bid/ask quotes, interest rate yields, and prepayment spreads and are included in Level 2. Cash balances of $0.6 million and $1.2 million at June 30, 2016 and 2015, respectively, are not included in the fair value hierarchy disclosure. As of June 30, 2016, the Company’s material financial assets and liabilities were reported at their current carrying values which approximate fair value given the short-term nature of less than a year, except for its note payable. As of June 30, 2016, the Company’s note payable was reported at its current carrying value which approximates fair value based on Level 3 unobservable inputs involving discounted cash flows and the estimated market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s credit risk.

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3. Inventories Inventories consisted of the following (in thousands): June 30, 201 6 June 30, 201 5 Raw materials $ 698 $ 870 Work in progress 133 162 Finished goods 232 359 Total $ 1,063 $ 1,391

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4. Property and Equipment Property and equipment consisted of the following (in thousands): June 30, 201 6 201 5 Computer hardware and software $ 106 $ 98 Office furniture and equipment 27 27 Machinery and equipment 6,523 6,378 Leasehold improvements 183 183 6,839 6,686 Less: accumulated depreciation and amortization (5,661 ) (4,827 ) Total $ 1,178 $ 1,859

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5. Commitments and Contingencies On November 11, 2010, the Company entered into an amendment to its facility lease (the “Lease Amendment”). Pursuant to the Lease Amendment, the term of the lease was extended by four years, through August 31, 2015, and the Company was granted an improvement allowance of $148,070 to be used in connection with the construction of alterations and refurbishment of improvements in the premises, which was used and reimbursed in the fiscal year ended June 30, 2012. The leasehold improvement allowance will be recorded as a reduction of rent expense on a straight-line basis over the term of the lease. On November 24, 2014, the Company entered into another amendment to its facility lease (the “Second Lease Amendment”), extended its lease by three years, from September 1, 2015, through August 31, 2018 (the “Second Extended Term”). In addition, under the Second Lease Amendment, the Company was granted an option to further extend the lease for a period of three years beyond August 31, 2018 (the “Option Term”), with the annual rent payable by the Company during the Option Term to be equal to the annual rent for comparable buildings, as described in the Second Lease Amendment. Under the operating lease, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $0.1 million was recorded as restricted cash in the condensed balance sheets as of June 30, 2016 and 2015, related to the letter of credit. Future minimum lease payments under the non-cancelable operating leases having initial terms of a year or more as of June 30, 2016, including the Lease Amendment, are as follows (in thousands): Fiscal year ending June 30, Operating Leases 2017 $ 1,001 2018 1,032 2019 173 Total minimum lease payments $ 2,206 Rent expense for fiscal years 2016, 2015 and 2014, was $0.9 million, $0.8 million and $0.6 million, respectively.

Note 6 - Distribution, License,

Note 6 - Distribution, License, Development and Commercialization Agreements	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 6. Distribution, License, Development and Commercialization Agreements Century On September 2, 2011, the Company signed a distribution agreement (the “Distribution Agreement”) with Century with respect to distribution of the Company’s planned microcutter products in Japan. Under the terms of a secured note purchase agreement, Century agreed to loan the Company an aggregate of up to $4.0 million, with principal due in September 30, 2016, subject to certain conditions, which principal due date was extended by two years effective July 1, 2014. Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. The note bears 5% annual interest which is payable quarterly in arrears through September 30, 2018, the maturity date when the total $4.0 million of principal becomes due. The timing of the repayment of the principal is subject to an uncertainty because in August 2016, Century asserted that the Company had an obligation to prepay Century’s loan in the amount of $4.0 million within ten days of receiving net proceeds from financing of over $44.0 million in April 2014, notwithstanding that the Company entered into an agreement with Century in July 2014 to extend the due date to September 30, 2018. Century further has asserted that the Company owes Century penalty interest at the incremental rate of 7% per annum, but has offered to waive it if the Company immediately repays the loan. Such interest would amount to $0.6 million as of June 30, 2016. Please see additional details related to this in Note 7. In return for the loan commitment, the Company granted Century distribution rights to the Company’s planned microcutter product line in Japan, and a right of first negotiation for distribution rights in Japan to future products. Century is responsible for securing regulatory approval from the Ministry of Health in Japan for the microcutter product line. In August 2013, Century filed for regulatory approval of the MicroCutter XCHANGE 30 blue and white reloads with the Pharmaceuticals and Medical Devices Agency and in April 2014, filed for the MicroCutter XCHANGE 30 stapler with TUV Rheinland Japan Ltd, a registered third-party agency in Japan and received approvals in late 2014 for both reloads and stapler, to market in Japan. Also, in January 2015, Century submitted an application to PMDA, relating to a change in the material of the reload insert component within the reloads, changing the distal tip of the reload insert material from a LCP to an IXEF, and received approval in August 2015, to market in Japan. Though approvals of the MicroCutter XCHANGE 30 stapler and reloads for marketing in Japan have been obtained, Century intends to wait until the Company releases the MicroCutter 5/80 to Century and Century will need to file additional regulatory approvals with the Ministry of Health to market the MicroCutter 5/80 in Japan. After approval for marketing in Japan, the Company would sell microcutter units to Century, who would then sell the microcutter devices to their customers in Japan. Proceeds from the note and granting the distribution rights were allocated to the note based on its aggregate fair value of $2.4 million at the dates of receipt. This fair value was determined by discounting cashflows using a discount rate of 18%, which the Company estimated a market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s. The remainder of the proceeds of $1.6 million was recognized as debt issuance discount and was allocated to the value of the distribution rights granted to Century under the Distribution Agreement and is included in deferred revenue. The deferred revenue will be recognized over the term of the Distribution Agreement, beginning upon the first sale by Century of the microcutter products in Japan which had not occurred as of June 30, 2016. The Company’s distribution agreement with Century pertaining to the PAS-Port system, originally dated June 16, 2003, as amended, was due to expire on July 31, 2014. Concurrently and in return for the amendment of the note, as discussed above, to extend the maturity date to September 30, 2018, the Company amended its distribution agreement with Century for the PAS-Port system, effective July 1, 2014, to, among other things, renew the contract for another five years, extending the expiration date to July 31, 2019. The note amendment was accounted for as the modification of the 2011 note agreement, as the value of the consideration provided by the Company in the form of additional distribution rights was estimated to be approximately equal to the reduction in the fair value of the note. Accordingly, the Company reduced the carrying value of the note of $3.1 million to its post-modification fair value of $2.6 million, and recorded the resulting incremental discount of $0.5 million as deferred revenue. The Company determined the fair value of the amended note using the discount rate of 18%, which the Company estimated as the market rate of borrowing as of the modification date that could be obtained by companies with credit risk similar to the Company’s. The incremental discount of $0.5 million will be amortized over the remaining term of the note using the effective interest rate method. The deferred revenue will be recognized over the term of the distribution agreement beginning upon the first sale by Century of the microcutter products in Japan. Cook Incorporated In June 2007, the Company entered into, and in September 2007 and in June 2009 amended, a license, development and commercialization agreement with Cook, to develop and commercialize a specialized device, referred to as the PFO device, designed to close holes in the heart from genetic heart defects known as patent foramen ovales (“PFOs”). Under the agreement, Cook funded certain development activities and the Company and Cook jointly developed the device. The Company’s significant deliverables under the arrangement were the license rights and the associated development activities. These deliverables were determined to represent one unit of accounting as there was no standalone value to the license rights. If developed, Cook would receive an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to make, have made, use, sell, offer for sale and import the PFO device. Under this agreement, the Company received no payments in the fiscal years ended June 30, 2016, 2015 and 2014. Amounts paid but not yet earned on the project are recorded as deferred revenue until such time as the related development expenses for certain project activities are incurred. A total of $0.4 million under this agreement has been recorded as deferred development revenue on the balance sheet as of June 30, 2016. On January 6, 2010, the Company and Cook mutually agreed to suspend work on the PFO project and, accordingly, the Company does not anticipate receiving any additional payments or recording any additional revenue related to this agreement in the foreseeable future. Intuitive Surgical On August 16, 2010, the Company entered into a license agreement with Intuitive Surgical Operations, Inc., or Intuitive Surgical, (the “License Agreement”) pursuant to which the Company granted to Intuitive Surgical a worldwide, sublicenseable, exclusive license to use the Company’s intellectual property in the robotics field in diagnostic or therapeutic medical procedures, but excluding vascular anastomosis applications, for an upfront license fee of $9.0 million. The Company is also eligible to receive a contingent payment related to achieving a certain sales volume. Each party has the right to terminate the License Agreement in the event of the other party’s uncured material breach or bankruptcy. Following any termination of the License Agreement, the licenses granted to Intuitive Surgical will continue, and except in the case of termination for the Company’s uncured material breach or insolvency, Intuitive Surgical’s payment obligations will continue as well. Under the License Agreement, Intuitive Surgical has rights to improvements in the Company’s technology and intellectual property over a specified period of time. The Company determined that there were two substantive deliverables under the License Agreement representing separate units of accounting: license rights to technology that existed as of August 16, 2010, and license rights to technology that may be developed over the following three years. The $9.0 million upfront license payment and $1.0 million premium on the stock purchase by Intuitive Surgical (see Note 8) were aggregated and allocated to the two units of accounting based upon the relative estimated selling prices of the deliverables. The relative estimated selling prices of the deliverables were determined using a probability weighted expected return model with significant inputs relating to the nature of potential future outcomes and the probability of occurrence of future outcomes. Based upon the relative estimated selling prices of the deliverables, $9.0 million of the total consideration of $10.0 million was allocated to the license rights to technology that existed as of August 16, 2010, that has been recognized as revenue in the fiscal year ended June 30, 2011, and $1.0 million was allocated to technology that may be developed over the following three years that is being recognized as revenue ratably over that three year period. In total, the revenue recognized for the fiscal years ended June 30, 2016, 2015 and 2014, related to this arrangement were $0, $0 and $41,000, respectively. The Company has fully recognized such revenue, and as of June 30, 2015 and 2016, no deferred revenue related to this arrangement. On December 31, 2015, the Company and Intuitive Surgical amended the license agreement, which was initially signed in August 2010, to include, among other things, an agreement providing for a feasibility evaluation and potential development of a surgical stapling cartridge for use with Intuitive Surgical’s da Vinci The feasibility evaluation allowed Intuitive Surgical to test and evaluate the Company’s microcutter technology. The six-month feasibility evaluation of the Company’s microcutter technology was completed successfully and Intuitive Surgical exercised its option to initiate a joint development program for an 8-millimeters-in-diameter surgical stapling cartridge for use with the da Vinci Pursuant to the agreement, the Company will receive further funding for development of the cartridge and tooling as well as a unit-based royalty on commercial sales. The Company determined that there were two substantive deliverables under the amended license agreement representing separate units of accounting: license rights to technology that existed as of December 30, 2015; and license rights to technology that may be developed over the following two years. The $2.0 million payment from the amended license agreement was aggregated and allocated to the two units of accounting based upon the relative estimated selling prices of the deliverables. The relative estimated selling prices of the deliverables were determined using a probability weighted expected return model with significant inputs relating to the nature of potential future outcomes and the probability of occurrence of future outcomes, which approximates fair value based on Level 3 unobservable inputs. Based upon the relative estimated selling prices of the deliverables, $1.4 million of the total consideration of $2.0 million was allocated to the license rights to technology that existed as of December 30, 2015, that was recognized as revenue in the three months ended March 31, 2016, and $0.6 million was allocated to technology that may be developed over the following two years that was being recognized as revenue ratably over that two year period. As of June 30, 2016, the Company recognized a total of $1.5 million of license and development revenue and as of June 30, 2016, the Company had a deferred revenue of $0.5 million related to this amended license agreement.

Note 7 - Notes Payable

Note 7 - Notes Payable	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. Notes Payable In connection with the Distribution Agreement with Century (see Note 6), the Company entered into a secured note purchase agreement and a related security agreement pursuant to which Century agreed to loan to the Company up to an aggregate of $4.0 million, which amount was received in the fiscal year ended June 30, 2012, and the secured note purchase agreement was amended effective July 1, 2014, to extend the principal due date by two years. Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. This note bears 5% annual interest which is payable quarterly in arrears on the last business day of March, June, September and December of each year through September 30, 2018, the maturity date when the total $4.0 million of principal becomes due. The debt issuance discount of approximately $2.1 million is reflected as a reduction in long-term debt and is being amortized as interest expense over the term of the note using the effective interest method. The note is secured by substantially all of the Company's assets, including the Company’s intellectual property related to the PAS-Port® Proximal Anastomosis System, but excluding all other intellectual property, until the note is repaid. There are no covenants associated with this debt. The Company made interest payments of $0.2 million for each of the fiscal years ended June 30, 2016, 2015 and 2014. The interest payable at June 30, 2016 and 2015, was $50,000 and $50,000, respectively, and included in other accrued liabilities in the accompanying balance sheets. In August 2016, Century asserted that the Company had an obligation to prepay Century’s loan in the amount of $4.0 million within ten days of receiving net proceeds from financing of over $44.0 million in April 2014, notwithstanding that the Company entered into an agreement with Century in July 2014 to extend the due date to September 30, 2018. Century further has asserted that the Company owes Century penalty interest at the incremental rate of 7% per annum, but has offered to waive it if the Company immediately repays the loan. Such interest would amount to $0.6 million as of June 30, 2016. The Company does not agree with Century’s assertions as the Company believes it had notified Century of the financing that occurred in April 2014 and the extension of the due date of the note agreement effectively waived the prepayment provisions of the loan. The Company is currently in discussions with Century to resolve this matter. The Company does not believe it is probable that Century would prevail in a legal resolution of this matter. Accordingly, the Company has not changed the classification of the note as a noncurrent liability as of June 30, 2016. Penalty interest has not been reflected in the financial statements as its payment is not considered probable. Additionally, the Company has not accelerated amortization of the remaining note discount ($0.9 million at June 30, 2016).

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 8. Stockholders’ Equity As of June 30, 2016 and June 30, 2015, the total number of shares that the Company is authorized to issue is 130,000,000 shares, with 125,000,000 shares designated as common stock and 5,000,000 shares designated as preferred stock. Common Stock Holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors. No dividends have been declared to date. In April 2014, the Company sold 3,737,500 shares of its common stock at $8.50 per share, and 191,474 shares of Series A Convertible Preferred Stock at $85 per share. The Series A convertible preferred stock is non-voting and is convertible into shares of its common stock at a conversion rate of 10 shares of common stock for each share of Series A convertible preferred stock, provided that conversion will be prohibited if, as a result, the holder and their affiliates would own more than 9.98% of the total number of shares of the Company’s common stock then outstanding unless the holder gives the Company at least 61 days prior notice of an intent to convert into shares of common stock that would cause the holder to own more than 9.98% of the total number of shares of common stock then issued and outstanding. Net proceeds from the financing to the Company were approximately $44.6 million. For fiscal year ended June 30, 2014, the Company recorded a deemed dividend of $1.9 million related to beneficial conversion feature of series A convertible preferred stock. A one-time beneficial conversion charge was due to the difference between the common stock price and conversion price on the closing date of the Company’s public offering in April 2014 . On August 3, 2011, the Company entered into the At The Market Issuance Sales Agreement (the “ATM Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), which provided for the sale of the Company’s common stock through MLV as the Company’s sales agent. The ATM Agreement expired on August 2, 2014. During the fiscal years ended June 30, 2014 and 2013, the Company received net proceeds of $0.4 million and $0.7 million, respectively, from the sale of an aggregate of 43,916 and 41,409 shares of common stock through MLV, respectively. During the fiscal years ended June 30, 2016 and 2015, the Company did not sell any shares of common stock through MLV. Preferred Stock The Company has 5,000,000 shares of authorized preferred stock issuable in one or more series. The Company can determine the number of shares constituting any series and the designation of such series and the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of common stock. The issuance of the preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of the Company or other corporate action. As of June 30, 2016, the Company had designated 250,000 shares of preferred stock as series A convertible preferred stock, and there were 191,474 shares of series A convertible preferred stock issued and outstanding. For the fiscal year ended June 30, 2014, the Company recorded a deemed dividend of $1.9 million related to beneficial conversion feature of series A convertible preferred stock. A one-time beneficial conversion charge was due to the difference between the common stock price and conversion price on the closing date of the Company’s public offering in April 2014 . Each share of Series A preferred stock is convertible into 10 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series A preferred stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding, unless the holder gives us at least 61 days prior notice of an intent to convert into shares of common stock that would cause the holder to own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of the Company’s Series A preferred stock will share ratably with the holders of the Company’s common stock on an as-if-converted basis. Shares of Series A preferred stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock will be required to alter or change adversely the powers, preferences or rights given to the Series A preferred stock (an increase the number of authorized shares of Series A preferred stock shall not constitute an adverse change) or enter into any agreement to do so. Shares of Series A Preferred Stock will not be entitled to receive any dividends, unless a cash dividend is declared by the Company’s board of directors to be paid to the holders of common stock, in which case the holders of Series A Preferred Stock will be entitled to receive a cash dividend equal to the amount of dividends declared on the common stock on an as-if-converted basis. Shares Reserved Shares of common stock reserved for future issuance are as follows: June 30, 201 6 Stock options and RSUs outstanding 1,542,993 Shares available for grant under stock option plan 35,652 Shares reserved for issuance upon conversion of Series A Preferred 1,914,740 Warrants for common stock — 3,493,385 Stock Options In 1997, the Company adopted the 1997 Equity Incentive Plan (the “1997 Plan”). The 1997 Plan provides for the granting of options to purchase common stock and the issuance of shares of common stock, subject to Company repurchase rights, to directors, employees and consultants. Certain options are immediately exercisable, at the discretion of the Board of Directors. Shares issued pursuant to the exercise of an unvested option are subject to the Company’s right of repurchase which lapses over periods specified by the board of directors, generally four years from the date of grant. In February 2006, the Company terminated all remaining unissued shares under the 1997 Plan. Although the 1997 Plan terminated, all outstanding options thereunder will continue to be governed by their existing terms. In October 2005, the Company’s Board of Directors adopted, and in December 2005 the stockholders approved, the 2005 Equity Incentive Plan, as amended (the “2005 Plan”). Pursuant to a series of amendments, a total of 1,140,000 shares of common stock have been reserved for issuance under the 2005 Plan as of the termination date. In October 2015, the Company terminated all remaining unissued shares under the 2005 Plan. Although the 2005 Plan terminated, all outstanding options thereunder will continue to be governed by their existing terms. On May 20, 2015, the Board of Directors of the Company adopted the Dextera Surgical Inc., Inducement Plan pursuant to which the Company reserved 40,000 shares for issuance under the Inducement Plan. The only persons eligible to receive grants of Stock Awards under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 – that is, generally, a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with the Company. A “Stock Award” is any right to receive the Company common stock granted under the Plan, including a nonstatutory stock option, a restricted stock award, a restricted stock unit award, a stock appreciation right, or any other stock award. At June 30, 2016, the Company reserved 529,116 shares for issuance under the Inducement Plan. On May 20, 2015, the Company’s new vice president of operations, was granted a stock option to purchase 40,000 shares of the Company common stock pursuant to the Inducement Plan. On October 15, 2015, the Company’s new president and chief executive officer, was granted a stock option to purchase 489,116 shares of the Company common stock pursuant to the Inducement Plan. In November 2015, the Company’s Board of Directors adopted, and in January 2016 the stockholders approved, the 2016 Equity Incentive Plan, as amended (the “2016 Plan”). A total of 711,992 shares of common stock have been reserved for issuance under the 2016 Plan as of June 30, 2016. Stock awards granted under the 2016 Plan may either be incentive stock options, nonstatutory stock options, stock appreciation rights or rights to acquire restricted or performance stock. Incentive stock options may be granted to employees with exercise prices of no less than the fair value of the common stock on the date of grant, as determined by the Board of Directors, and nonstatutory options may be granted to employees, directors or consultants at exercise prices of no less than the fair value. If, at the time the Company grants an option, the awardee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant. Options may be granted with vesting terms as determined by the Board of Directors. Options expire no more than 10 years after the date of grant, or earlier if employment is terminated. Award activity under all Plans is as follows: Outstanding Options Shares Available for Grant Number of Shares Weighted- Average Exercise Price Per Share Balance at June 30, 2013 147,519 393,590 $ 24.26 Shares reserved 100,000 — — Restricted stock awards granted (9,266 ) — — Options granted (194,450 ) 194,450 11.83 Options forfeited 27,888 (27,888 ) 39.36 Balance at June 30, 2014 71,691 560,152 $ 19.39 Shares reserved 540,000 — — Restricted stock awards granted (29,000 ) — — Options granted (250,961 ) 250,961 6.90 Options forfeited 355,534 (355,534 ) 14.46 Balance at June 30, 2015 687,264 455,579 $ 16.48 Shares reserved 409,132 — — Options granted (1,249,956 ) 1,249956 2.84 Options forfeited 189,212 (189,212 ) 24.32 Balance at June 30, 2016 35,652 1,516,323 $ 4.33 The following table summarizes information about options outstanding, vested and exercisable at June 30, 2016: Options Outstanding Options exercisable Exercise Prices Number of Shares Weighted- Average Remaining Contractual Life (years) Weighted Average Exercise Price per Share Number of Shares Weighted Average Exercise Price per Share $ 2.79 – $ 2.79 68,300 6.87 2.79 1,770 2.79 $ 2.80 – $ 2.80 1,090,156 7.88 2.80 81,367 2.80 $ 3.50 – $ 38.20 357,867 4.43 9.30 218,330 11.43 Total outstanding 1,516,323 7.02 $ 4.33 301,467 $ 9.05 Options vested and expected to vest 1,324,625 7.00 $ 4.52 The weighted average remaining contractual life for all currently exercisable options as of June 30, 2016, was 4.62 years. The aggregate intrinsic value as of June 30, 2016, of all outstanding options was $0, options vested and expected to vest was $0 and options exercisable was $0. The aggregate intrinsic value as of June 30, 2015, of all outstanding options was $53,000, options vested and expected to vest was $43,000 and options exercisable was $0. The weighted-average estimated grant date fair value of options granted to employees and directors during fiscal years 2016, 2015 and 2014 was $2.93, $3.67 and $8.00 per share, respectively. There were no options exercised during fiscal years 2016, 2015 and 2014. The fair value of all stock options actually vesting in fiscal years 2016, 2015 and 2014 was $0, $568,000 and $528,000, respectively. Rest ricted Stock Units and Awards The following table summarizes information about restricted stock activity. Shares Non-vested restricted stock at June 30, 2013 4,600 Awarded 9,266 Vested (12,266 ) Forfeited — Non-vested restricted stock at June 30, 2014 1,600 Awarded 29,000 Vested (1,600 ) Forfeited (10,000 ) Non-vested restricted stock at June 30, 2015 19,000 Awarded 40,000 Vested (32,330 ) Forfeited — Non-vested restricted stock at June 30, 2016 26,670 The aggregate intrinsic value as of June 30, 2016, of all non-vested restricted stock awards was $48,000, and awards expected to vest was $43,000. The estimated grant date fair value of awards granted during fiscal years 2016, 2015 and 2014, was $4.75, $11.40 and $11.48 per share, respectively. The intrinsic value of all awards granted during fiscal years 2016, 2015 and 2014 was $190,000, $330,000 and $106,000, respectively. The fair value of all stock awards actually vesting in fiscal years 2016, 2015 and 2014 was $88,000, $19,000 and $165,000, respectively. The fair value of each restricted stock award is estimated based upon the closing price of the Company’s common stock on the grant date. Share-based compensation expense related to restricted stock units and awards is recognized over the requisite service period as adjusted for estimated forfeitures. Warrants The Company’s warrants to purchase 399,121 shares of common stock expired in September 2014.

Note 9 - Reductions in Force

Note 9 - Reductions in Force	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 9 – Reductions in Force During the fiscal year 2015, the Company reduced its workforce by 24 positions to conserve cash and to match its use of cash with its stage of development. The Company’s decision to engage in the corporate restructurings and layoffs resulted from the necessary improvements required for the MicroCutter 5/80. As a result, the Company recorded a restructuring charge of $0.3 million for severance and other benefits which was fully paid during the fiscal year 2015. The charges were included in all departmental expenses.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10. Income Taxes Deferred income taxes reflect the net tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts unused for income tax purposes. Significant components of the Company’s deferred tax assets are as follows (in thousands): June 30, 201 6 201 5 Net operating loss carry-forwards $ 68,914 $ 62,457 Research credits 3,891 3,448 Fixed asset depreciation 48 31 Stock compensation 393 546 Deferred revenue 151 158 Other 1,123 885 Total deferred tax assets 74,520 67,525 Valuation allowance (74,520 ) (67,525 ) Net deferred tax assets $ — $ — Realization of the deferred tax assets is dependent upon future income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net valuation allowance increased by approximately $6.9 million, $6.9 million and $4.4 million during fiscal years ended June 30, 2016, 2015 and 2014, respectively. As of June 30, 2016, the Company had federal net operating loss carry-forwards and research and development tax credit carry-forwards of approximately $189.8 million and $3.6 million, respectively. The net operating loss carry-forwards begin to expire in the fiscal year 2018. The federal credits begin to expire in fiscal year 2021 if not utilized. Additionally, the Company’s state net operating loss carry-forwards of approximately $127.4 million begin to expire in the fiscal year 2017 and the Company has state research and development tax credit carry-forwards of $4.2 million. The California state credit carry-forwards have an unlimited carry-forward period and the State of Arizona credits begin to expire in fiscal year 2024. Included in the valuation allowance balance as of June 30, 2016, is $0.2 million related to the exercise of stock options which are not reflected as an expense for financial reporting purposes. Accordingly, any future reduction in the valuation allowance relating to this amount will be credited directly to equity and not reflected as an income tax benefit in the Statement of Operations. The reconciliation of income tax benefits attributable to the net loss computed at the U.S. federal statutory rates to the income tax benefit recorded (in thousands): Fiscal Year Ended June 30, 201 6 201 5 201 4 Tax benefit at U.S. statutory rate $ 5,449 $ (6,520 ) $ (5,768 ) Loss for which no tax benefit is currently recognizable (5,606 ) 6,341 5,584 Stock based compensation 140 160 164 Other, net 17 19 20 $ — $ — $ — Utilization of the net operating loss carry-forwards and credit carry-forwards may be subject to a substantial annual limitation due to the limitations set forth in Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (“Internal Revenue Code”), and similar state provisions. In the fiscal year ended June 30, 2010, the Company completed a detailed analysis to determine whether an ownership change under Section 382 of the Internal Revenue Code had occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of the net operating loss carry-forwards and credit carry-forwards attributable to periods before the change. Any subsequent ownership changes could further limit the use of net operating losses and credits. The Company concluded that approximately $4.9 million of federal net operating loss carry-forwards, $1.5 million of federal credit carry-forwards, $122,000 of California state credit carry-forwards and approximately $19.5 million of California state net operating loss carry-forwards are significantly limited to offset future income, if any. However, the Company issued additional shares in fiscal years 2011 through 2014, that may have triggered another ownership change. A Section 382 study to determine the impact of these issuances has not been performed. If a change in ownership was triggered, the net operating loss carry-forwards and credit carry-forwards included in the Deferred Tax Assets could be further limited. The reductions are reflected in the carry-forward amounts included above. At June 30, 2016, the Company had unrecognized tax benefits of $1.3 million, all of which would not currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Amount Balance at June 30, 2013 $ 939 Additions based on tax positions related to current year 74 Balance at June 30, 2014 1,013 Additions based on tax positions related to prior years 26 Additions based on tax positions related to current year 82 Balance at June 30, 2015 1,121 Additions based on tax positions related to prior years 56 Additions based on tax positions related to current year 79 Balance at June 30, 2016 $ 1,256 The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2016. The tax years 1998 through 2015 remain open to examination by one or more major taxing jurisdictions to which the Company is subject.

Note 11 - Employee Benefit Plan

Note 11 - Employee Benefit Plan	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 1 1 . Employee Benefit Plan In January 2001, the Company adopted a 401(k) Profit Sharing Plan that allows voluntary contributions by eligible employees. Employees may elect to contribute up to the maximum allowed under the Internal Revenue Service regulations. The Company may make discretionary contributions as determined by the Board of Directors. No amount was contributed by the Company to the plan during fiscal years ended June 30, 2016, 2015 or 2014.

Note 12 - Indemnification

Note 12 - Indemnification	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Indemnification [Text Block]	Note 1 2 . Indemnification From time to time, the Company enters into contracts that require the Company, upon the occurrence of certain contingencies, to indemnify parties against third-party claims. These contingent obligations primarily relate to (i) claims against the Company’s customers for violation of third-party intellectual property rights caused by the Company’s products; (ii) claims resulting from personal injury or property damage resulting from the Company’s activities or products; (iii) claims by the Company’s office lessor arising out of the Company’s use of the premises; and (iv) agreements with the Company’s officers and directors under which the Company may be required to indemnify such persons for liabilities arising out of their activities on behalf of the Company. Because the obligated amounts for these types of agreements usually are not explicitly stated, the overall maximum potential amount of these obligations cannot be reasonably estimated. No liabilities have been recorded for these obligations on the Company’s consolidated balance sheets as of June 30, 2016 or 2015, as there are no amounts currently estimable and probable of payment.

Note 13 - Consolidated Financia

Note 13 - Consolidated Financial Information by Quarter	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 1 3 . Consolidated Financial Information by Quarter Consolidated Financial Information by Quarter (unaudited) Fiscal Year 201 6 : 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter (In thousands, except per share data) Total net revenue $ 755 $ 700 $ 1,886 $ 714 Gross profit (loss) on product sales (1) (286 ) (206 ) (453 ) (423 ) Net loss (4,642 ) (4,087 ) (3,027 ) (4,231 ) Basic and diluted net loss per common share (0.52 ) (0.46 ) (0.34 ) (0.47 ) Shares used in computing basic and diluted net loss per common share 8,896 8,901 8,916 8,928 Fiscal Year 201 5 : 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter (In thousands, except per share data) Total net revenue $ 1,068 $ 657 $ 564 $ 701 Gross profit (loss) on product sales (1) (582 ) (305 ) (259 ) (167 ) Net loss (5,065 ) (5,442 ) (4,824 ) (3,851 ) Basic and diluted net loss per common share (0.57 ) (0.61 ) (0.54 ) (0.44 ) Shares used in computing basic and diluted net loss per common share 8,895 8,895 8,896 8,896 (1) Gross profit is computed as total net product sales less cost of product sales.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Going Concern The Company has incurred cumulative net losses of $205.7 million through June 30, 2016, and negative cash flows from operating activities and expects to incur losses for the next several years. As of June 30, 2016, the Company had approximately $12.7 million of cash, cash equivalents and short-term investments, and $4.0 million of debt principal outstanding. The Company believes that the existing cash, cash equivalents and short-term investments will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted for at least the next nine months, subject to the ultimate resolution of the following uncertainty. The Company does not agree with Century’s assertions as the Company believes that it had notified Century of the financing that occurred in April 2014 and the extension of the due date of the note agreement effectively waived the prepayment provisions of the loan. The Company is currently in discussions with Century to resolve this matter. The Company does not believe it is probable that Century would prevail in a legal resolution of this matter. Accordingly, the Company has not changed the classification of the note as a noncurrent liability as of June 30, 2016. Penalty interest has not been reflected in the financial statements as its payment is not considered probable. Additionally, the Company has not accelerated amortization of the remaining note discount ($0.9 million at June 30, 2016). If the Company is required to repay the $4.0 million loan from Century along with the related penalty interest prior to September 30, 2018, this will reduce the period during which the existing cash, cash equivalents and short-term investments will be sufficient to meet the Company’s anticipated cash needs to less than six months from June 30, 2016, which would severely impair our ability to continue our business unless we are able to raise other funds to repay this debt. The Company may be able to extend these time periods to the extent that it decreases its planned expenditures, or raises additional capital. The Company would need to further reduce expenses in advance of the date on which it would exhaust its cash, cash equivalents and short-term investments in the event that it is unable to complete a financing, strategic or commercial transaction in the near term to ensure that it has sufficient capital to meet its obligations and continue on a path designed to create and preserve stockholders’ value. In order to satisfy its longer term liquidity requirements, the Company may seek to sell additional equity or debt securities, obtain a credit facility, enter into product development, license or distribution agreements with third parties or divest one or more of its commercialized products or products in development. The sale of additional equity or convertible debt securities could result in significant dilution to its stockholders, particularly in light of the prices at which its common stock has been recently trading. In addition, if the Company raises additional funds through the sale of equity securities, new investors could have rights superior to its existing stockholders. If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with its common stock and could contain covenants that would restrict its operations. Any product development, licensing, distribution or sale agreements that the Company enters into may require it to relinquish valuable rights, including with respect to commercialized products or products in development that the Company would otherwise seek to commercialize or develop it selves. The Company may not be able to obtain sufficient additional financing or enter into a strategic transaction in a timely manner. Its need to raise capital may require it to accept terms that may harm its business or be disadvantageous to its current stockholders. The Company’s consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuations as a going concern is contingent upon its ability to generates revenue and cash flow to meet its obligations on a timely basis and its ability to raise financing. The Company’s plans may be adversely impacted if it fails to realize its assumed levels of revenues and expenses or savings from its cost reduction activities. However, there can be no assurance that the Company will be able to generate cash flows and raise such funds if and when they are required. Failure to obtain future funding when needed or on acceptable terms would adversely affect its ability to fund operations and continues as a going concern. These matters raise substantial doubt about the ability of the Company to continue in existence as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Basis of Presentation and Principles of Consolidation [Policy Text Block]	Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of Dextera Surgical Inc., and its wholly-owned subsidiary in Germany. All significant intercompany balances and transactions have been eliminated in consolidation.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On February 16, 2016, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse split of its outstanding common stock (the “Reverse Split”) which had the effect of reducing the number of outstanding shares of common stock from 89,344,777 to 8,934,452, effective February 17, 2016. Any fractional shares of common stock resulting from the Reverse Split were settled in cash equal to the fraction of a share to which the holder was entitled. As a result of the Reverse Split, the Company reclassified its consolidated balance sheets total par value of approximately $80,000 from common stock to additional paid-in capital for the reporting periods. All shares of common stock, stock options, warrants to purchase common stock, the conversion rate of preferred stock and per share information presented in the consolidated financial statements have been adjusted to reflect the Reverse Split on a retroactive basis for all periods presented and all share information is rounded down to the nearest whole share after reflecting the Reverse Split.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense).
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could materially differ from these estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company’s cash and cash equivalents are maintained in checking, money market, commercial paper and corporate debt securities investment accounts. The Company considers all highly liquid investments with maturities remaining on the date of purchase of three months or less to be cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable consists of trade receivables and other receivables. Accounts receivable are recorded at net realizable value, which approximates fair value. The Company evaluates the collectability of accounts receivable on a case-by-case basis and makes adjustments to the bad debt reserve for expected losses. The Company considers factors such as ability to pay, bankruptcy, credit ratings, payment history and past-due status of the accounts. If circumstances related to customers change, estimates of recoverability would be further adjusted. For the fiscal year ended June 30, 2014, the Company recovered $33,000 of bad debt reserve that was recorded in the fiscal year ended June 30, 2013.
Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]	Available-for-Sale Securities Available-for-sale securities consist primarily of corporate debt securities, commercial paper, and certificates of deposit, and, by the Company's investment policy, restrict exposure to any single corporate issuer by imposing concentration limits. Although maturities may extend beyond one year, it is management's intent that these securities are available for use in current operations. The Company held investments in marketable securities as of June 30, 2016 and 2015, with maturity dates of less than one year for short-term and greater than one year for long-term. The Company records its marketable securities at fair value and classifies them as available-for-sale. The cost of securities sold is based on the specific-identification method. Interest on securities classified as available-for-sale is included in interest income. Unrealized gains or losses on available-for-sale securities are classified as other comprehensive income or loss and reported as a separate component of stockholders’ equity until realized. When the resulting fair value is significantly below cost basis and/or the significant decline has lasted for an extended period of time, the Company performs an evaluation to determine whether the marketable equity security is other than temporarily impaired. The evaluation that the Company uses to determine whether a marketable equity security is other than temporarily impaired is based on the specific facts and circumstances present at the time of assessment, which include significant quantitative and qualitative assessments and estimates regarding credit ratings, collateralized support, the length of time and significance of a security’s loss position and intent and ability to hold a security to maturity or forecasted recovery. Investments are summarized as follows (in thousands): As of June 30, 201 6 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Commercial paper – Short-term $ 999 $ — $ — $ 999 Corporate debt securities – Short-term 8,095 — (4 ) 8,091 Total $ 9,094 $ — $ (4 ) $ 9,090 As of June 30, 201 5 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Corporate debt securities – Short-term $ 12,978 $ — $ (6 ) $ 12,972 Corporate debt securities – Long-term 3,972 — (2 ) 3,970 Total $ 16,950 $ — $ (8 ) $ 16,942 The following table summarizes the gross unrealized losses and fair values of investments in an unrealized loss position as of June 30, 2016, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands): June 30, 2016 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) Total $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) June 30, 2015 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 ) Total $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 ) The Company reviews investments for other-than-temporary impairment. It was determined that unrealized losses at June 30, 2016 and 2015, are temporary in nature, because the changes in market value for these securities resulted from the fluctuating interest rates, rather than a deterioration of the credit worthiness of the issuers. The Company is unlikely to experience losses if these securities are held to maturity. In the event that the Company disposes of these securities before maturity, it is expected that any losses will be immaterial. The following tables summarizes contractual underlying maturities of the Company’s available-for-sale investments at June 30, 2016 (in thousands): June 30, 2016 Due one year or less Marketable Securities: Cost Fair Value Commercial paper $ 999 $ 999 Corporate debt securities 8,095 8,091 Total $ 9,094 $ 9,090
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Under an operating lease for its facility in Redwood City, California, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $0.1 million at June 30, 2016 and 2015, has been recorded as restricted cash in the accompanying balance sheets, related to the letter of credit (see Note 5).
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Certain Other Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, long-term investments and accounts receivable. The Company places its cash, cash equivalents, short-term and long-term investments with high-credit quality financial institutions. The Company is exposed to credit risk in the event of default by the institutions holding the cash, cash equivalents, short-term and long-term investments to the extent of the amounts recorded on the balance sheet. The Company sells its products to hospitals in the U.S. and Europe and to distributors in Europe, Japan and Saudi Arabia that resell the products to hospitals. The Company does not require collateral to support credit sales. The Company has had insignificant credit losses to date. The following table illustrates total net revenue from the geographic location in which the Company’s customers are located and sales revenue by product line. Net revenue by geographic location: Fiscal Year Ended June 30, 2016 2015 2014 United States 37 % 50 % 45 % Japan 34 % 28 % 29 % Germany 21 % 14 % 15 % Rest of world 8 % 8 % 11 % Sales revenue by product line (in thousands): Fiscal Year Ended June 30, 2016 2015 2014 Microcutter $ 351 $ 684 $ 488 Cardiac (automated anastomotic systems) 2,178 2,238 3,017 Total $ 2,529 $ 2,922 $ 3,505 The following table illustrates concentrations of credit risk for the periods presented. Percent of Total Net Revenue for Fiscal Year Ended June 30, Percent of Total Accounts Receivable as of June 30, 2016 2015 2014 2016 2015 Century Medical 21 % 28 % 29 % 33 % 46 % Herz-Und Diabeteszentrum 8 % 10 % 12 % — — Iona Surgical 1 % 1 % — 20 % 9 % As of June 30, 2016, 2015 and 2014, and for the years then ended, no other customer accounted for equal to or greater than 10% of net revenue or account receivable balances. The Company does not believe that accounts receivable from Century Medical, Herz-Und Diabeteszentrum and Iona Surgical represent a significant credit risk based on past collection experiences and the general creditworthiness of these customers. The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities.
Inventory, Policy [Policy Text Block]	Inventories Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, to determine whether adjustments for impairment are required. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Further reduced demand may result in the need for additional inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows. All long-lived assets are in the United States, and through June 30, 2016, there have been no indications of impairment; therefore, the Company has recorded no such losses.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title has transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment. The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection. Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses consist of costs incurred for internally sponsored research and development, direct expenses, research-related overhead expenses, and costs incurred on development contracts. Research and development costs are charged to research and development expenses as incurred.
Clinical Trials [Policy Text Block]	Clinical Trials The Company accrues and expenses costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. The Company determines the estimates through discussion with internal clinical personnel and outside service providers as to progress or stage of completion of trials or services and the agreed upon fee to be paid for such services. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trial.
Deferred Charges, Policy [Policy Text Block]	Deferred Rent Rent expense is recognized on a straight-line basis over the non-cancelable term of the Company’s facility operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent. The current portion of deferred rent is recorded as other accrued liabilities, while the non-current portion is recorded in non-current accrued liabilities.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2016.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in a single reporting segment. Management uses one measurement of profitability and does not segregate its business for internal reporting purposes. All of the Company’s long-lived assets are maintained in the United States.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period without consideration of potential common shares. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding for the period less the dilutive potential common shares for the period determined using the treasury-stock method. Dilutive potential common share equivalents are excluded from the computation of net loss per share in the loss periods as their effect would be antidilutive. For purposes of this calculation, options, warrants and underlying convertible preferred shares to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. In the years the Preferred Stock was outstanding, the two-class method was used to calculate basic and diluted earnings (loss) per common share since it is a participating security under ASC 260 Earnings per Share The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except per share data): Fiscal Year Ended June 30, 2016 2015 2014 Numerator: Net loss $ (15,987 ) $ (19,182 ) $ (16,966 ) Deemed dividend related to beneficial conversion feature of convertible preferred stock — — (1,915 ) Net loss allocable to common stockholders $ (15,987 ) $ (19,182 ) $ (18,881 ) Denominator: Weighted-average shares outstanding allocable to common stockholders 8,910 8,895 5,833 Denominator for basic and diluted net loss per share allocable to common stockholders 8,910 8,895 5,833 Basic and diluted net loss per share allocable to common stockholders $ (1.79 ) $ (2.16 ) $ (3.24 ) The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation for the fiscal years ended June 30, 2016, 2015 and 2014, because their effect would be antidilutive (in thousands): As of June 30, 2016 2015 2014 Options to purchase common stock 1,516 456 560 Non-vested restricted stock units and awards 27 19 2 Shares reserved for issuance upon conversion of Series A Preferred 1,915 1,915 1,915 Warrants — — 399 3,458 2,390 2,876
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, is measured on the grant date, based on the fair value-based measurement of the award and is recognized as an expense over the requisite service period which generally equals the vesting period of each grant. The Company recognizes compensation expense using the accelerated method and the Company accounts for the non-employee share-based grants pursuant to ASC 505-50, Equity Based Payments to Non-Employees. The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements: Fiscal Year Ended June 30, 2016 2015 2014 Risk-free interest rate 0.47% – 1.50% 0.21% – 1.65% 0.91% – 1.49% Dividend yield — — — Weighted-average expected life (in years) 4.2 – 5.0 4.3 – 4.9 3.8 – 4.6 Volatility 65% – 75% 65% – 72% 66% – 80% The Company estimates the expected life of options granted based on historical exercise and post-vest cancellation patterns, which the Company believes are representative of future behavior . The risk-free interest rate for the expected term of each option is based on a risk-free zero-coupon spot interest rate at the time of grant. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. The expected volatility is based on the Company’s historical stock price. The Company estimates forfeitures in calculating the expense related to stock-based compensation. The Company recorded stock-based compensation expenses for awards granted to employees under ASC 718 of $1.2 million, or $0.13 per share, $1.1 million, or $0.13 per share, and $0.9 million, or $0.16 per share for the fiscal years ended June 30, 2016, 2015 and 2014, respectively. The Company recorded stock-based compensation expenses for awards granted to non-employees under ASC 505-50 of $9,103, or $0 per share for fiscal year ended June 30, 2016 and did not record any for June 30, 2015. The Company recorded stock-based compensation expenses for awards granted to non-employees under ASC 505-50 of $0.1 million, or $0.02 per share for fiscal year ended June 30, 2014. In December 2014, the Company cancelled certain options granted to employees in excess of the stock plan limits, which resulted in the recognition of $0.2 million of unamortized expense recorded as stock-based compensation expenses. Total compensation expense related to unvested awards not yet recognized is approximately $1.0 million at June 30, 2016, and is expected to be recognized over a weighted average period of 3 years. Included in the statement of operations is the following non-cash stock-based compensation expense for the periods reported, including non-employee stock based compensation expense and the amortization of deferred compensation (in thousands): Fiscal Year Ended June 30, 2016 2015 2014 Cost of product sales $ 106 $ 63 $ 117 Research and development 203 183 133 Selling, general and administrative 867 903 770 Total $ 1,176 $ 1,149 $ 1,020
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which amends the current guidance by replacing the incurred loss model with a forward-looking expected loss model. The standard is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company will be evaluating the impact of the adoption of this guidance on its consolidated financial statements and related disclosures. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients," amending guidance in the new revenue standard on transition, collectability, noncash consideration and the presentation of sales taxes and other similar taxes. The amendments clarify that for a contract to be considered completed at transition, substantially all of the revenue must have been recognized under the existing GAAP. The amendments also clarified the collectability assessment and expanded circumstances under which nonrefundable consideration may receive revenue recognition when collectability of the remainder is not probable. It clarified that the fair value of noncash consideration should be measured at contract inception for determining the transaction price. The amendments permit an entity to make a policy election to exclude from the transaction price sales taxes and similar taxes. The effective date and transition requirements for these amendments are the same as those of the new revenue standard (ASU 2014-09, as amended by ASU 2015-14). The Company will be evaluating the impact of the adoption of this guidance on the Company’s consolidated financial statements and related disclosures. In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing," adding clarification, while retaining the core principles in the revenue guidance. For identifying performance obligations, the ASU clarifies when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow entities to disregard items that are immaterial in the context of a contract. For licensing, the ASU clarifies how an entity should evaluate the nature of its promise in granting a license of IP, which will determine whether it recognizes revenue over time (“symbolic IP”) or at a point in time (“functional IP”).The effective date and transition requirements for these amendments are the same as those of the new revenue standard (ASU 2014-09, as amended by ASU 2015-14). The Company will be evaluating the impact of the adoption of this guidance on the Company’s consolidated financial statements and related disclosures. In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting, In March 2016, the FASB issued an accounting standard update ASU 2016-08, which clarifies the implementation guidance on principal versus agent considerations under the new revenue recognition standard, ASU 2014-09 (Topic 606), Revenue from Contracts with Customers. It requires the entity to determine whether the nature of its promise is to provide that good or service to the customer (that is, the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (that is, the entity is an agent). This determination is based upon whether the entity controls the good or service before it is transferred to the customer. The amendment will be effective for annual reporting periods beginning after December 15, 2017, which will be the Company’s fiscal year 2019 (beginning July 1, 2018). The Company will be evaluating the impact of the adoption of this guidance on the Company’s consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases, In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued an accounting standard update which requires an entity measuring inventory other than last-in, first-out (LIFO) or the retail inventory method to measure inventory at the lower of cost and net realizable value. When evidence exists that the net realizable value of inventory is lower than its costs, the difference will be recognized as a loss in the statement of operations. The standard is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The Company will be evaluating the impact of the adoption of this standard on the Company’s consolidated financial statements and disclosures. In April 2015, the FASB issued an accounting standard update which provides guidance on whether a cloud computing arrangement includes a software license to a customer of such an arrangement. If a cloud computing arrangement includes a software license, a customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses, otherwise the customer should account for the arrangement as a service contract. The standard is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The standard can be applied prospectively to all arrangements entered into or materially modified after the effective date, or retrospectively. The adoption of this guidance is not expected to have an impact on the Company’s consolidated financial statements and disclosures. In April 2015, the FASB issued an accounting standard update which requires an entity to present debt issuance costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. The standard is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The standard will be applied retrospectively to each prior period presented. The Company will be evaluating the impact of the adoption of this guidance on the Company’s consolidated balance sheets. In February 2015, the FASB issued an amendment to the accounting standard regarding the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation model. The amendments in this update are effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of this update is not expected to have a material effect on the Company’s consolidated financial statements or disclosures. In August 2014, the FASB issued an accounting standard update related to the disclosures around going concern. The new standard provides guidance around management’s responsibility to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The new standard is effective for the annual periods and interim periods within those annual periods beginning after December 15, 2016. Early application is permitted. The Company will be evaluating the impact of the adoption of this guidance on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606): Revenue from Contracts with Customers Revenue Recognition

Note 1 - Organization and Sum24

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	As of June 30, 201 6 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Commercial paper – Short-term $ 999 $ — $ — $ 999 Corporate debt securities – Short-term 8,095 — (4 ) 8,091 Total $ 9,094 $ — $ (4 ) $ 9,090 As of June 30, 201 5 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale securities: Corporate debt securities – Short-term $ 12,978 $ — $ (6 ) $ 12,972 Corporate debt securities – Long-term 3,972 — (2 ) 3,970 Total $ 16,950 $ — $ (8 ) $ 16,942
Schedule of Unrealized Loss on Investments [Table Text Block]	June 30, 2016 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) Total $ 8,091 $ (4 ) $ — $ — $ 8,091 $ (4 ) June 30, 2015 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 ) Total $ 11,959 $ (6 ) $ 3,525 $ (2 ) $ 15,484 $ (8 )
Investments Classified by Contractual Maturity Date [Table Text Block]	June 30, 2016 Due one year or less Marketable Securities: Cost Fair Value Commercial paper $ 999 $ 999 Corporate debt securities 8,095 8,091 Total $ 9,094 $ 9,090
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Fiscal Year Ended June 30, 2016 2015 2014 United States 37 % 50 % 45 % Japan 34 % 28 % 29 % Germany 21 % 14 % 15 % Rest of world 8 % 8 % 11 %
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Fiscal Year Ended June 30, 2016 2015 2014 Microcutter $ 351 $ 684 $ 488 Cardiac (automated anastomotic systems) 2,178 2,238 3,017 Total $ 2,529 $ 2,922 $ 3,505
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Percent of Total Net Revenue for Fiscal Year Ended June 30, Percent of Total Accounts Receivable as of June 30, 2016 2015 2014 2016 2015 Century Medical 21 % 28 % 29 % 33 % 46 % Herz-Und Diabeteszentrum 8 % 10 % 12 % — — Iona Surgical 1 % 1 % — 20 % 9 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Fiscal Year Ended June 30, 2016 2015 2014 Numerator: Net loss $ (15,987 ) $ (19,182 ) $ (16,966 ) Deemed dividend related to beneficial conversion feature of convertible preferred stock — — (1,915 ) Net loss allocable to common stockholders $ (15,987 ) $ (19,182 ) $ (18,881 ) Denominator: Weighted-average shares outstanding allocable to common stockholders 8,910 8,895 5,833 Denominator for basic and diluted net loss per share allocable to common stockholders 8,910 8,895 5,833 Basic and diluted net loss per share allocable to common stockholders $ (1.79 ) $ (2.16 ) $ (3.24 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of June 30, 2016 2015 2014 Options to purchase common stock 1,516 456 560 Non-vested restricted stock units and awards 27 19 2 Shares reserved for issuance upon conversion of Series A Preferred 1,915 1,915 1,915 Warrants — — 399 3,458 2,390 2,876
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Fiscal Year Ended June 30, 2016 2015 2014 Risk-free interest rate 0.47% – 1.50% 0.21% – 1.65% 0.91% – 1.49% Dividend yield — — — Weighted-average expected life (in years) 4.2 – 5.0 4.3 – 4.9 3.8 – 4.6 Volatility 65% – 75% 65% – 72% 66% – 80%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Fiscal Year Ended June 30, 2016 2015 2014 Cost of product sales $ 106 $ 63 $ 117 Research and development 203 183 133 Selling, general and administrative 867 903 770 Total $ 1,176 $ 1,149 $ 1,020

Note 2 - Fair Value Measureme25

Note 2 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of June 30, 201 6 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 3,029 $ — $ — $ 3,029 Short-term investments: Commercial paper — 999 — 999 Corporate debt securities — 8,091 — 8,091 Total assets at fair value $ 3,029 $ 9,090 $ — $ 12,119 As of June 30, 201 5 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 6,399 $ — $ — $ 6,399 Corporate debt securities — 668 — 668 Short-term investments: Corporate debt securities — 12,972 — 12,972 Long-term investments: Corporate debt securities — 3,970 — 3,970 Total assets at fair value $ 6,399 $ 17,610 $ — $ 24,009

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 201 6 June 30, 201 5 Raw materials $ 698 $ 870 Work in progress 133 162 Finished goods 232 359 Total $ 1,063 $ 1,391

Note 4 - Property and Equipme27

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following (in thousands): June 30, 201 6 201 5 Computer hardware and software $ 106 $ 98 Office furniture and equipment 27 27 Machinery and equipment 6,523 6,378 Leasehold improvements 183 183 6,839 6,686 Less: accumulated depreciation and amortization (5,661 ) (4,827 ) Total $ 1,178 $ 1,859

Note 5 - Commitments and Cont28

Note 5 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Fiscal year ending June 30, Operating Leases 2017 $ 1,001 2018 1,032 2019 173 Total minimum lease payments $ 2,206

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Stock Options Roll Forward [Table Text Block]	June 30, 201 6 Stock options and RSUs outstanding 1,542,993 Shares available for grant under stock option plan 35,652 Shares reserved for issuance upon conversion of Series A Preferred 1,914,740 Warrants for common stock — 3,493,385
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Outstanding Options Shares Available for Grant Number of Shares Weighted- Average Exercise Price Per Share Balance at June 30, 2013 147,519 393,590 $ 24.26 Shares reserved 100,000 — — Restricted stock awards granted (9,266 ) — — Options granted (194,450 ) 194,450 11.83 Options forfeited 27,888 (27,888 ) 39.36 Balance at June 30, 2014 71,691 560,152 $ 19.39 Shares reserved 540,000 — — Restricted stock awards granted (29,000 ) — — Options granted (250,961 ) 250,961 6.90 Options forfeited 355,534 (355,534 ) 14.46 Balance at June 30, 2015 687,264 455,579 $ 16.48 Shares reserved 409,132 — — Options granted (1,249,956 ) 1,249956 2.84 Options forfeited 189,212 (189,212 ) 24.32 Balance at June 30, 2016 35,652 1,516,323 $ 4.33
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options exercisable Exercise Prices Number of Shares Weighted- Average Remaining Contractual Life (years) Weighted Average Exercise Price per Share Number of Shares Weighted Average Exercise Price per Share $ 2.79 – $ 2.79 68,300 6.87 2.79 1,770 2.79 $ 2.80 – $ 2.80 1,090,156 7.88 2.80 81,367 2.80 $ 3.50 – $ 38.20 357,867 4.43 9.30 218,330 11.43 Total outstanding 1,516,323 7.02 $ 4.33 301,467 $ 9.05 Options vested and expected to vest 1,324,625 7.00 $ 4.52
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Shares Non-vested restricted stock at June 30, 2013 4,600 Awarded 9,266 Vested (12,266 ) Forfeited — Non-vested restricted stock at June 30, 2014 1,600 Awarded 29,000 Vested (1,600 ) Forfeited (10,000 ) Non-vested restricted stock at June 30, 2015 19,000 Awarded 40,000 Vested (32,330 ) Forfeited — Non-vested restricted stock at June 30, 2016 26,670

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30, 201 6 201 5 Net operating loss carry-forwards $ 68,914 $ 62,457 Research credits 3,891 3,448 Fixed asset depreciation 48 31 Stock compensation 393 546 Deferred revenue 151 158 Other 1,123 885 Total deferred tax assets 74,520 67,525 Valuation allowance (74,520 ) (67,525 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Fiscal Year Ended June 30, 201 6 201 5 201 4 Tax benefit at U.S. statutory rate $ 5,449 $ (6,520 ) $ (5,768 ) Loss for which no tax benefit is currently recognizable (5,606 ) 6,341 5,584 Stock based compensation 140 160 164 Other, net 17 19 20 $ — $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Amount Balance at June 30, 2013 $ 939 Additions based on tax positions related to current year 74 Balance at June 30, 2014 1,013 Additions based on tax positions related to prior years 26 Additions based on tax positions related to current year 82 Balance at June 30, 2015 1,121 Additions based on tax positions related to prior years 56 Additions based on tax positions related to current year 79 Balance at June 30, 2016 $ 1,256

Note 13 - Consolidated Financ31

Note 13 - Consolidated Financial Information by Quarter (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Quarterly Financial Information [Table Text Block]	1st Quarter 2nd Quarter 3rd Quarter 4th Quarter (In thousands, except per share data) Total net revenue $ 755 $ 700 $ 1,886 $ 714 Gross profit (loss) on product sales (1) (286 ) (206 ) (453 ) (423 ) Net loss (4,642 ) (4,087 ) (3,027 ) (4,231 ) Basic and diluted net loss per common share (0.52 ) (0.46 ) (0.34 ) (0.47 ) Shares used in computing basic and diluted net loss per common share 8,896 8,901 8,916 8,928 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter (In thousands, except per share data) Total net revenue $ 1,068 $ 657 $ 564 $ 701 Gross profit (loss) on product sales (1) (582 ) (305 ) (259 ) (167 ) Net loss (5,065 ) (5,442 ) (4,824 ) (3,851 ) Basic and diluted net loss per common share (0.57 ) (0.61 ) (0.54 ) (0.44 ) Shares used in computing basic and diluted net loss per common share 8,895 8,895 8,896 8,896

Note 1 - Organization and Sum32

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	Feb. 17, 2016shares	Dec. 31, 2014USD ($)	Apr. 30, 2014USD ($)	Jun. 30, 2016USD ($)shares	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)shares	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2016USD ($)$ / sharesshares		Jun. 30, 2015USD ($)$ / sharesshares		Jun. 30, 2014USD ($)$ / shares		Jun. 30, 2016USD ($)shares	Jun. 30, 2016USD ($)shares	Feb. 16, 2016shares	Jul. 01, 2014USD ($)
Reverse Stock Split [Member] | June 30, 2015 [Member] | Reclassification from Common Stock to Additional Paid-in Capital [Member]
Prior Period Reclassification Adjustment												$ 80,000
Reverse Stock Split [Member] | June 30, 2014 [Member] | Reclassification from Common Stock to Additional Paid-in Capital [Member]
Prior Period Reclassification Adjustment												80,000
Reverse Stock Split [Member] | Reclassification from Common Stock to Additional Paid-in Capital [Member]
Current Period Reclassification Adjustment												$ 80,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10											10		10		10
Certificates of Deposit [Member]
Restricted Cash and Cash Equivalents				$ 100,000				$ 100,000				$ 100,000		$ 100,000				$ 100,000	$ 100,000
Microcutter Products [Member]
Revenue, Net																		$ 1,800,000
MicroCutter 5/80 [Member]
Revenue, Net												$ 400,000		700,000		$ 500,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate				7.00%								7.00%						7.00%	7.00%
Interest Expense, Debt Penalties												$ 600,000
Century Medical [Member]
Debt Instrument, Face Amount				$ 4,000,000								4,000,000						$ 4,000,000	$ 4,000,000
Debt Instrument, Unamortized Discount				900,000								900,000						900,000	900,000		$ 2,100,000
Non-employees [Member]
Allocated Share-based Compensation Expense												$ 9,103		0		$ 100,000
Allocated Share-based Compensation, Per Share | $ / shares												$ 0				$ 0.02
Minimum [Member]
Property, Plant and Equipment, Useful Life												3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life												5 years
Employee Stock Option [Member] | Unamortized Expense Related to Share-based Awards Granted to Employees in Excess of Plan Limits [Member]
Allocated Share-based Compensation Expense		$ 200,000
Restricted Cash and Cash Equivalents				104,000				104,000				$ 104,000		104,000				104,000	104,000
Impairment of Long-Lived Assets Held-for-use												0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense												0
Revenue, Net				714,000	$ 1,886,000	$ 700,000	$ 755,000	701,000	$ 564,000	$ 657,000	$ 1,068,000	4,055,000		2,990,000		$ 3,615,000
Net Income (Loss) Attributable to Parent				(4,231,000)	$ (3,027,000)	$ (4,087,000)	$ (4,642,000)	$ (3,851,000)	$ (4,824,000)	$ (5,442,000)	$ (5,065,000)	(15,987,000)	[1]	(19,182,000)	[1]	(16,966,000)	[1]		205,700,000
Cash, Cash Equivalents, and Short-term Investments				12,700,000								12,700,000						12,700,000	12,700,000
Long-term Debt, Gross				$ 4,000,000								$ 4,000,000						$ 4,000,000	$ 4,000,000
Number of Reportable Segments												1
Proceeds from Issuance or Sale of Equity			$ 44,600,000
Allocated Share-based Compensation Expense												$ 1,200,000		$ 1,100,000		$ 900,000
Allocated Share-based Compensation, Per Share | $ / shares												$ 0.13		$ 0.13		$ 0.16
Common Stock, Shares, Outstanding | shares	8,934,452			8,927,830				8,895,521				8,927,830		8,895,521				8,927,830	8,927,830	89,344,777
Allowance for Loan and Lease Loss, Recovery of Bad Debts																$ 33,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized				$ 1,000,000								$ 1,000,000						$ 1,000,000	$ 1,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition												3 years
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Note 1 - Investments (Details)

Note 1 - Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Short-term Commercial Paper [Member]
Amortized Cost	$ 999
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	999
Short-term Corporate Debt Securities [Member]
Amortized Cost	8,095	$ 12,978
Gross Unrealized Gains
Gross Unrealized Losses	(4)	(6)
Fair Value	8,091	12,972
Long-term Corporate Debt Securities [Member]
Amortized Cost		3,972
Gross Unrealized Gains
Gross Unrealized Losses		(2)
Fair Value		3,970
Amortized Cost	9,094	16,950
Gross Unrealized Gains
Gross Unrealized Losses	(4)	(8)
Fair Value	$ 9,090	$ 16,942

Note 1 - Investment Securities

Note 1 - Investment Securities in a Continuous Unrealized Loss Position (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Corporate Debt Securities [Member]
Less than 12 months Fair Value	$ 8,091	$ 11,959
Less than 12 months Gross Unrealized Losses	(4)	(6)
12 months or greater Fair Value		3,525
12 months or greater Gross Unrealized Losses		(2)
Total Fair Value	8,091	15,484
Total Gross Unrealized Losses	(4)	(8)
Less than 12 months Fair Value	8,091	11,959
Less than 12 months Gross Unrealized Losses	(4)	(6)
12 months or greater Fair Value		3,525
12 months or greater Gross Unrealized Losses		(2)
Total Fair Value	8,091	15,484
Total Gross Unrealized Losses	$ (4)	$ (8)

Note 1 - Summary of Contractual

Note 1 - Summary of Contractual Underlying Maturities of Investments (Details) $ in Thousands	Jun. 30, 2016USD ($)
Short-term Commercial Paper [Member]
Cost	$ 999
Fair Value	999
Corporate Debt Securities [Member]
Cost	8,095
Fair Value	8,091
Cost	9,094
Fair Value	$ 9,090

Note 1 - Net Revenue from Geogr

Note 1 - Net Revenue from Geographic Location (Details) - Geographic Concentration Risk [Member] - Sales Revenue, Product Line [Member]	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
UNITED STATES
Revenue by geographic location	37.00%	50.00%	45.00%
JAPAN
Revenue by geographic location	34.00%	28.00%	29.00%
GERMANY
Revenue by geographic location	21.00%	14.00%	15.00%
All Other Countries [Member]
Revenue by geographic location	8.00%	8.00%	11.00%

Note 1 - Sales Revenue by Produ

Note 1 - Sales Revenue by Product Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Microcutter Products [Member]
Revenue by product line	$ 351	$ 684	$ 488
Cardiac [Member]
Revenue by product line	2,178	2,238	3,017
Revenue by product line	$ 2,529	$ 2,922	$ 3,505

Note 1 - Concentration of Risk,

Note 1 - Concentration of Risk, by Risk Factor (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Century Medical [Member] | Sales Revenue, Net [Member]
Revenue by geographic location	21.00%	28.00%	29.00%
Century Medical [Member] | Accounts Receivable [Member]
Revenue by geographic location	33.00%	46.00%
Herz-Und Diabeteszentrum [Member] | Sales Revenue, Net [Member]
Revenue by geographic location	8.00%	10.00%	12.00%
Herz-Und Diabeteszentrum [Member] | Accounts Receivable [Member]
Revenue by geographic location
Iona Surgical [Member] | Sales Revenue, Net [Member]
Revenue by geographic location	1.00%	1.00%
Iona Surgical [Member] | Accounts Receivable [Member]
Revenue by geographic location	20.00%	9.00%

Note 1 - Computation of Basic a

Note 1 - Computation of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended								12 Months Ended						225 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2016		Jun. 30, 2015		Jun. 30, 2014		Jun. 30, 2016
Net loss	$ (4,231,000)	$ (3,027,000)	$ (4,087,000)	$ (4,642,000)	$ (3,851,000)	$ (4,824,000)	$ (5,442,000)	$ (5,065,000)	$ (15,987,000)	[1]	$ (19,182,000)	[1]	$ (16,966,000)	[1]	$ 205,700,000
Deemed dividend related to beneficial conversion feature of convertible preferred stock													(1,915,000)
Net loss allocable to common stockholders									$ (15,987,000)		$ (19,182,000)		$ (18,881,000)
Weighted-average shares outstanding allocable to common stockholders (in shares)									8,910		8,895		5,833
Shares used in computing basic and diluted net loss per share allocable to common stockholders(1) (in shares)	8,928	8,916	8,901	8,896	8,896	8,896	8,895	8,895	8,910	[2]	8,895	[2]	5,833	[2]
Basic and diluted net loss per common share (in dollars per share)	$ (0.47)	$ (0.34)	$ (0.46)	$ (0.52)	$ (0.44)	$ (0.54)	$ (0.61)	$ (0.57)	$ (1.79)	[2]	$ (2.16)	[2]	$ (3.24)	[2]
[1]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.
[2]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.

Note 1 - Antidilutive Securitie

Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Option [Member]
Antidilutive securities (in shares)	1,516	456	560
Restricted Stock [Member]
Antidilutive securities (in shares)	27	19	2
Common Stock Shares Reserved for Future Issuance [Member]
Antidilutive securities (in shares)	1,915	1,915	1,915
Warrant [Member]
Antidilutive securities (in shares)			399
Antidilutive securities (in shares)	3,458	2,390	2,876

Note 1 - Black-Scholes Valuatio

Note 1 - Black-Scholes Valuation Assumptions (Details)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Minimum [Member]
Risk-free interest rate	0.47%	0.21%	0.91%
Weighted-average expected life (in years)	4 years 73 days	4 years 109 days	3 years 292 days
Volatility	65.00%	65.00%	66.00%
Maximum [Member]
Risk-free interest rate	1.50%	1.65%	1.49%
Weighted-average expected life (in years)	5 years	4 years 328 days	4 years 219 days
Volatility	75.00%	72.00%	80.00%
Dividend yield

Note 1 - Non-Cash Stock-Based C

Note 1 - Non-Cash Stock-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Cost of Sales [Member]
Non-cash stock-based compensation	$ 106	$ 63	$ 117
Research and Development Expense [Member]
Non-cash stock-based compensation	203	183	133
Selling, General and Administrative Expenses [Member]
Non-cash stock-based compensation	867	903	770
Non-cash stock-based compensation	$ 1,176	$ 1,149	$ 1,020

Note 2 - Fair Value Measureme43

Note 2 - Fair Value Measurements (Details Textual) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Liabilities, Fair Value Disclosure, Recurring	$ 0
Cash	$ 600,000	$ 1,200,000

Note 2 - Fair Value Measureme44

Note 2 - Fair Value Measurements on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	$ 3,029	$ 6,399
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents	3,029	6,399
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents		668
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents
Corporate Debt Securities with Maturity Less than 90 Days [Member] | Fair Value, Measurements, Recurring [Member]
Cash equivalents		668
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Fair Value
Investments
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Fair Value
Investments
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Long-term Corporate Debt Securities [Member]
Fair Value
Investments
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value	3,029	6,399
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Fair Value	999
Investments	999
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Fair Value	8,091	12,972
Investments	8,091	12,972
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Long-term Corporate Debt Securities [Member]
Fair Value		3,970
Investments		3,970
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value	9,090	17,610
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Fair Value
Investments
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Fair Value
Investments
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Long-term Corporate Debt Securities [Member]
Fair Value
Investments
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Total assets at fair value
Fair Value, Measurements, Recurring [Member] | Short-term Commercial Paper [Member]
Fair Value	999
Investments	999
Fair Value, Measurements, Recurring [Member] | Short-term Corporate Debt Securities [Member]
Fair Value	8,091	12,972
Investments	8,091	12,972
Fair Value, Measurements, Recurring [Member] | Long-term Corporate Debt Securities [Member]
Fair Value		3,970
Investments		3,970
Fair Value, Measurements, Recurring [Member]
Total assets at fair value	12,119	24,009
Short-term Commercial Paper [Member]
Fair Value	999
Investments	999
Short-term Corporate Debt Securities [Member]
Fair Value	8,091	12,972
Investments	8,091	12,972
Long-term Corporate Debt Securities [Member]
Fair Value		3,970
Investments		3,970
Fair Value	9,090	16,942
Investments	$ 9,090	$ 16,942

Note 3 - Summary of Inventories

Note 3 - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Raw materials	$ 698	$ 870
Work in progress	133	162
Finished goods	232	359
Total	$ 1,063	$ 1,391

Note 4 - Summary of Property an

Note 4 - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Computer Equipment [Member]
Property and equipment gross	$ 106	$ 98
Office Equipment [Member]
Property and equipment gross	27	27
Machinery and Equipment [Member]
Property and equipment gross	6,523	6,378
Leasehold Improvements [Member]
Property and equipment gross	183	183
Property and equipment gross	6,839	6,686
Less: accumulated depreciation and amortization	(5,661)	(4,827)
Total	$ 1,178	$ 1,859

Note 5 - Commitments and Cont47

Note 5 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Aug. 31, 2015
Restricted Cash, Letter of Credit [Member]
Restricted Cash and Cash Equivalents	$ 100,000	$ 100,000
Restricted Cash and Cash Equivalents	104,000	104,000
Leasehold Improvements, Gross				$ 148,070
Operating Leases, Rent Expense	$ 900,000	$ 800,000	$ 600,000

Note 5 - Future Minimum Lease P

Note 5 - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2016USD ($)
2,017	$ 1,001
2,018	1,032
2,019	173
Total minimum lease payments	$ 2,206

Note 6 - Distribution, Licens49

Note 6 - Distribution, License, Development and Commercialization Agreements (Details Textual) - USD ($)	Dec. 31, 2015	Jul. 01, 2014	Dec. 27, 2011	Sep. 30, 2011	Sep. 02, 2011	Aug. 16, 2010	Apr. 30, 2014	Sep. 30, 2011	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2012	Jun. 30, 2011
Intuitive Surgical [Member] | Initial Licensing Agreement [Member]
Deferred Revenue, Current										$ 0	$ 0	$ 0
Licenses Revenue						$ 9,000,000					0	0	$ 41,000
Common Stock Premium						1,000,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received						$ 10,000,000
Deferred Revenue, Noncurrent															$ 1,000,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Patented Technology [Member]
Proceeds from License Fees Received	$ 1,400,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Developed Technology Rights [Member]
Proceeds from License Fees Received									$ 600,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member]
Deferred Revenue, Current										500,000	500,000
Proceeds from License Fees Received	$ 2,000,000
Licenses Revenue										1,500,000
Cook Incorporated [Member]
Deferred Revenue, Current										400,000	400,000
Proceeds from License Fees Received											0	0	$ 0
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount					$ 4,000,000									$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%			5.00%
Fair Value Inputs, Discount Rate					18.00%
Debt Instrument, Unamortized Discount					$ 1,600,000					500,000	500,000
Deferred Revenue										$ 500,000	$ 500,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate										7.00%	7.00%
Interest Expense, Debt Penalties											$ 600,000
Century Medical [Member]
Debt Instrument, Face Amount										$ 4,000,000	4,000,000
Proceeds from Secured Notes Payable			$ 2,000,000	$ 2,000,000				$ 2,000,000
Notes Payable, Fair Value Disclosure		$ 2,600,000			$ 2,400,000
Debt Instrument, Unamortized Discount		$ 2,100,000								900,000	900,000
Distribution Agreement Term of Extension		5 years
Notes Payable		$ 3,100,000
Deferred Revenue, Current										569,000	569,000	403,000
Proceeds from Issuance or Sale of Equity							$ 44,600,000
Deferred Revenue, Noncurrent										$ 2,499,000	$ 2,499,000	$ 2,125,000

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Dec. 27, 2011	Sep. 30, 2011	Apr. 30, 2014	Sep. 30, 2011	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jul. 01, 2014	Jun. 30, 2012	Sep. 02, 2011
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount									$ 4,000,000	$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%		5.00%
Debt Instrument, Unamortized Discount					$ 500,000					$ 1,600,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate					7.00%
Interest Expense, Debt Penalties					$ 600,000
Century Medical [Member]
Interest Expense, Debt					200,000	$ 200,000	$ 200,000
Debt Instrument, Face Amount					4,000,000
Proceeds from Secured Notes Payable	$ 2,000,000	$ 2,000,000		$ 2,000,000
Debt Instrument, Unamortized Discount					900,000			$ 2,100,000
Interest Payable, Current					$ 50,000	$ 50,000
Proceeds from Issuance or Sale of Equity			$ 44,600,000

Note 8 - Stockholders' Equity51

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	Oct. 15, 2015	May 20, 2015	Sep. 30, 2014	Apr. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Oct. 31, 2005
MLV [Member]
Stock Issued During Period, Shares, New Issues					0	0	43,916	41,409
Proceeds from Issuance of Common Stock							$ 400,000	$ 700,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized					250,000
Stock Issued During Period, Shares, New Issues				191,474
Preferred Stock, Shares Outstanding					191,474
Share Price				$ 85
Convertible Preferred Stock, Shares Issued upon Conversion				10	10
Common Stock Ownership Threshold, Preferred Stock Conversion				9.98%	9.98%
Dividends Payable							1,900,000
Preferred Stock, Shares Issued					191,474
Dividends, Preferred Stock							$ 1,900,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues				3,737,500			3,737,500
Share Price				$ 8.50
1997 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					4 years
2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									1,140,000
Inducement Plan [Member] | Vice President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		40,000
Inducement Plan [Member] | President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	489,116
Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		40,000			529,116
2016 Plan [Member] | Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					711,992
Share-based Compensation, Options, Minimum Exercise Price, Percentage of Fair Vaule					110.00%
Share-based Compensation, Options, Maximum Exercisable Period					5 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value					$ 43,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value					$ 190,000	$ 330,000	$ 106,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 4.75	$ 11.40	$ 11.48
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					$ 88,000	$ 19,000	$ 165,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested					$ 48,000
Stock Shares Authorized					130,000,000	130,000,000
Common Stock, Shares Authorized					125,000,000	125,000,000
Preferred Stock, Shares Authorized					5,000,000	5,000,000
Preferred Stock, Shares Outstanding					191,474	191,474
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					0	0	0
Number of Votes					1
Proceeds from Issuance or Sale of Equity				$ 44,600,000
Proceeds from Issuance of Common Stock						$ (65,000)	$ 29,863,000
Preferred Stock, Shares Issued					191,474	191,474
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,249,956	250,961	194,450
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					4 years 226 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value					$ 0	$ 53,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value					0	43,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value					$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 2.93	$ 3.67	$ 8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					$ 0	$ 568,000	$ 528,000
Class of Warrant or Right, Expired During Period			399,121

Note 8 - Common Stock Reserved

Note 8 - Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Series A Preferred Stock [Member]
Shares reserved for issuance upon conversion of Series A Preferred (in shares)	1,914,740
Stock options and RSUs outstanding (in shares)	1,542,993
Shares available for grant under stock option plan (in shares)	35,652	687,264	71,691	147,519
Shares reserved for issuance upon conversion of Series A Preferred (in shares)	409,132	540,000	100,000
Warrants for common stock (in shares)
(in shares)	3,493,385

Note 8 - Option Activity Under

Note 8 - Option Activity Under All Plans (Details) - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Balance (in shares)	687,264	71,691	147,519
Balance (in shares)	455,579	560,152	393,590
Balance (in dollars per share)	$ 16.48	$ 19.39	$ 24.26
Shares reserved (in shares)				409,132	540,000	100,000
Restricted stock awards granted (in shares)		(29,000)	(9,266)
Options granted (in shares)	(1,249,956)	(250,961)	(194,450)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,249,956	250,961	194,450
Options granted (in dollars per share)	$ 2.84	$ 6.90	$ 11.83
Options forfeited (in shares)	189,212	355,534	27,888
Options forfeited (in shares)	(189,212)	(355,534)	(27,888)
Options forfeited (in dollars per share)	$ 24.32	$ 14.46	$ 39.36
Balance (in shares)	35,652	687,264	71,691
Balance (in shares)	1,516,323	455,579	560,152
Balance (in dollars per share)	$ 4.33	$ 16.48	$ 19.39
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$ 4.33	$ 19.39	$ 24.26	$ 4.33	$ 16.48	$ 19.39

Note 8 - Stock Options Outstand

Note 8 - Stock Options Outstanding, Vested and Exercisable (Details) - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Range One [Member]
Exercise price, lower limit (in dollars per share)	$ 2.79
Exercise price, upper limit (in dollars per share)	$ 2.79
Options Outstanding, Number of Shares (in shares)	68,300
Options Outstanding, Weighted- Average Remaining Contractual Life	6 years 317 days
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$ 2.79
Options exercisable, Number of Shares (in shares)	1,770
Options exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$ 2.79
Range Two [Member]
Exercise price, lower limit (in dollars per share)	2.80
Exercise price, upper limit (in dollars per share)	$ 2.80
Options Outstanding, Number of Shares (in shares)	1,090,156
Options Outstanding, Weighted- Average Remaining Contractual Life	7 years 321 days
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$ 2.80
Options exercisable, Number of Shares (in shares)	81,367
Options exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$ 2.80
Range Three [Member]
Exercise price, lower limit (in dollars per share)	3.50
Exercise price, upper limit (in dollars per share)	$ 38.20
Options Outstanding, Number of Shares (in shares)	357,867
Options Outstanding, Weighted- Average Remaining Contractual Life	4 years 156 days
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$ 9.30
Options exercisable, Number of Shares (in shares)	218,330
Options exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$ 11.43
Options Outstanding, Number of Shares (in shares)	1,516,323	455,579	560,152	393,590
Options Outstanding, Weighted- Average Remaining Contractual Life	7 years 7 days
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$ 4.33	$ 16.48	$ 19.39	$ 24.26
Options exercisable, Number of Shares (in shares)	301,467
Options exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$ 9.05
Options vested and expected to vest, Number of Shares (in shares)	1,324,625
Options vested and expected to vest, Weighted- Average Remaining Contractual Life	7 years
Options vested and expected to vest, Weighted Average Exercise Price per Share (in dollars per share)	$ 4.52

Note 8 - Restricted Stock Activ

Note 8 - Restricted Stock Activity (Details) - shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Restricted Stock [Member]
Non-vested restricted stock (in shares)	19,000	1,600	4,600
Awarded (in shares)	40,000	29,000	9,266
Vested (in shares)	(32,330)	(1,600)	(12,266)
Forfeited (in shares)		10,000
Non-vested restricted stock (in shares)	26,670	19,000	1,600
Forfeited (in shares)		(10,000)
Awarded (in shares)		29,000	9,266

Note 9 - Reductions in Force (D

Note 9 - Reductions in Force (Details Textual) $ in Millions	12 Months Ended
	Jun. 30, 2015USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	24
Severance Costs	$ 0.3

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
State and Local Jurisdiction [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 4,200,000
Exercise of Stock Options [Member]
Deferred Tax Assets, Valuation Allowance	200,000
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	4,900,000
Tax Credit Carryforward, Amount	1,500,000
California Franchise Tax Board [Member]
Operating Loss Carryforwards	19,500,000
Tax Credit Carryforward, Amount	122,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	6,900,000	$ 6,900,000	$ 4,400,000
Operating Loss Carryforwards	189,800,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	3,600,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	127,400,000
Deferred Tax Assets, Valuation Allowance	74,520,000	67,525,000
Unrecognized Tax Benefits	$ 1,256,000	$ 1,121,000	$ 1,013,000	$ 939,000

Note 10 - Deferred Tax Assets (

Note 10 - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Net operating loss carry-forwards	$ 68,914	$ 62,457
Research credits	3,891	3,448
Fixed asset depreciation	48	31
Stock compensation	393	546
Deferred revenue	151	158
Other	1,123	885
Total deferred tax assets	74,520	67,525
Valuation allowance	(74,520)	(67,525)
Net deferred tax assets

Note 10 - Effective Income Tax

Note 10 - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Tax benefit at U.S. statutory rate	$ 5,449	$ (6,520)	$ (5,768)
Loss for which no tax benefit is currently recognizable	(5,606)	6,341	5,584
Stock based compensation	140	160	164
Other, net	$ 17	$ 19	$ 20

Note 10 - Unrecognized Tax Bene

Note 10 - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Balance	$ 1,121	$ 1,013	$ 939
Additions based on tax positions related to current year	79	82	74
Balance	1,256	1,121	$ 1,013
Additions based on tax positions related to prior years	$ 56	$ 26

Note 11 - Employee Benefit Pl61

Note 11 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Defined Benefit Plan, Contributions by Employer	$ 0	$ 0	$ 0

Note 12 - Indemnification (Deta

Note 12 - Indemnification (Details Textual) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Indemnification Agreement [Member]
Loss Contingency Accrual	$ 0	$ 0

Note 13 - Financial Information

Note 13 - Financial Information by Quarter (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands		3 Months Ended								12 Months Ended						225 Months Ended
		Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2016		Jun. 30, 2015		Jun. 30, 2014		Jun. 30, 2016
Revenue, Net		$ 714,000	$ 1,886,000	$ 700,000	$ 755,000	$ 701,000	$ 564,000	$ 657,000	$ 1,068,000	$ 4,055,000		$ 2,990,000		$ 3,615,000
Gross profit (loss) on product sales	[1]	(423,000)	(453,000)	(206,000)	(286,000)	(167,000)	(259,000)	(305,000)	(582,000)
Net Income (Loss) Attributable to Parent		$ (4,231,000)	$ (3,027,000)	$ (4,087,000)	$ (4,642,000)	$ (3,851,000)	$ (4,824,000)	$ (5,442,000)	$ (5,065,000)	$ (15,987,000)	[2]	$ (19,182,000)	[2]	$ (16,966,000)	[2]	$ 205,700,000
Basic and diluted net loss per common share (in dollars per share)		$ (0.47)	$ (0.34)	$ (0.46)	$ (0.52)	$ (0.44)	$ (0.54)	$ (0.61)	$ (0.57)	$ (1.79)	[3]	$ (2.16)	[3]	$ (3.24)	[3]
Shares used in computing basic and diluted net loss per common share (in shares)		8,928	8,916	8,901	8,896	8,896	8,896	8,895	8,895	8,910	[3]	8,895	[3]	5,833	[3]
[1]	Gross profit is computed as total net product sales less cost of product sales.
[2]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.
[3]	All per share amounts and shares of Dextera Surgical common stock issued and outstanding for all periods have been retroactively adjusted to reflect Dextera Surgical's one-for-ten reverse stock split of its common stock, which was effective February 17, 2016.